Clovis Oncology (CLVSQ) 10-Q 5 May 22 2022 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2022	Apr. 29, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Entity File Number	001-35347
Entity Registrant Name	Clovis Oncology, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0475355
Entity Address, Address Line One	5500 Flatiron Parkway, Suite 100
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	303
Local Phone Number	625-5000
Title of 12(b) Security	Common Stock
Trading Symbol	CLVS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		143,879,140
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001466301
Amendment Flag	false

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues:
Product revenue	$ 34,247	$ 38,053
Product revenue - extensible list	Product	Product
Operating expenses:
Research and development	$ 42,250	$ 52,805
Selling, general and administrative	29,213	29,941
Other operating expenses	3,730	3,707
Total expenses	84,606	96,064
Operating loss	(50,359)	(58,011)
Other income (expense):
Interest expense	(9,100)	(8,037)
Foreign currency loss	(978)	(546)
Other income	148	183
Other income (expense), net	(9,930)	(8,400)
Loss before income taxes	(60,289)	(66,411)
Income tax benefit	120	134
Net loss	(60,169)	(66,277)
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax	435	(80)
Other comprehensive income (loss)	435	(80)
Comprehensive loss	$ (59,734)	$ (66,357)
Loss per basic and diluted common share:
Basic net loss per common share	$ (0.44)	$ (0.64)
Diluted net loss per common share	$ (0.44)	$ (0.64)
Basic weighted average common shares outstanding	138,205	104,246
Diluted weighted average common shares outstanding	138,205	104,246
Product
Operating expenses:
Cost of sales	$ 8,070	$ 8,268
Intangible asset amortization
Operating expenses:
Cost of sales	$ 1,343	$ 1,343

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 122,241	$ 143,428
Accounts receivable, net	27,296	26,868
Inventories, net	14,504	13,688
Prepaid research and development expenses	4,928	2,397
Other current assets	16,566	11,706
Total current assets	185,535	198,087
Inventories	106,118	109,848
Property and equipment, net	5,987	6,554
Right-of-use assets, net	18,675	19,109
Intangible assets, net	59,029	60,371
Goodwill	63,074	63,074
Other assets	13,111	15,790
Total assets	451,529	472,833
Current liabilities:
Accounts payable	22,332	27,308
Accrued research and development expenses	34,314	35,121
Lease liabilities	3,556	3,414
Borrowings under financing agreement	17,000	8,500
Other accrued expenses	44,630	50,871
Total current liabilities	121,832	125,214
Long-term lease liabilities - less current portion	19,004	19,731
Convertible senior notes	437,284	436,772
Borrowings under financing agreement - less current portion	176,715	169,956
Total liabilities	754,835	751,673
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized, no shares issued and outstanding at March 31, 2022 and December 31, 2021
Common stock, $0.001 par value per share, 200,000,000 shares authorized at March 31, 2022 and December 31, 2021, respectively; 143,869,226 and 129,109,543 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	144	129
Additional paid-in capital	2,676,965	2,641,712
Accumulated other comprehensive loss	(42,995)	(43,430)
Accumulated deficit	(2,937,420)	(2,877,251)
Total stockholders' deficit	(303,306)	(278,840)
Total liabilities and stockholders' deficit	$ 451,529	$ 472,833

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
CONSOLIDATED BALANCE SHEETS
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	143,869,226	129,109,543
Common stock, shares outstanding	143,869,226	129,109,543

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2020	$ 104	$ 2,498,179	$ (44,304)	$ (2,612,727)	$ (158,748)
Beginning Balance (in shares) at Dec. 31, 2020	103,699,109
Exercise of stock options		27			27
Exercise of stock options (in shares)	5,609
Issuance of common stock from vesting of restricted stock units	$ 1	(1)
Issuance of common stock from vesting of restricted stock units (in shares)	853,239
Share-based compensation expense		4,039			4,039
Foreign currency translation adjustments			(80)		(80)
Net loss				(66,277)	(66,277)
Ending Balance at Mar. 31, 2021	$ 105	2,502,244	(44,384)	(2,679,004)	(221,039)
Ending Balance (in shares) at Mar. 31, 2021	104,557,957
Beginning Balance at Dec. 31, 2021	$ 129	2,641,712	(43,430)	(2,877,251)	$ (278,840)
Beginning Balance (in shares) at Dec. 31, 2021	129,109,543				129,109,543
Issuance of common stock from vesting of restricted stock units	$ 1	(1)
Issuance of common stock from vesting of restricted stock units (in shares)	889,273
Share-based compensation expense		6,632			$ 6,632
Foreign currency translation adjustments			435		435
Issuance of common stock, net of issuance costs	$ 14	28,622			28,636
Issuance of common stock, net of issuance costs (in shares)	13,870,410
Net loss				(60,169)	(60,169)
Ending Balance at Mar. 31, 2022	$ 144	$ 2,676,965	$ (42,995)	$ (2,937,420)	$ (303,306)
Ending Balance (in shares) at Mar. 31, 2022	143,869,226				143,869,226

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss	$ (60,169)	$ (66,277)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense	6,632	4,039
Depreciation and amortization	1,923	2,241
Amortization of debt issuance costs	558	639
Other	368	877
Changes in operating assets and liabilities:
Accounts receivable	(765)	4,732
Inventory	3,685	3,665
Prepaid and accrued research and development expenses	(1,323)	2,125
Other operating assets and liabilities	(4,879)	(5,005)
Accounts payable	(4,818)	(6,290)
Other accrued expenses	293	(2,636)
Net cash used in operating activities	(58,495)	(61,890)
Investing activities
Purchases of property and equipment	(62)	(118)
Net cash used in investing activities	(62)	(118)
Financing activities
Proceeds from sale of common stock, net of issuance costs	28,636
Proceeds from borrowings under financing agreement	9,221	13,802
Proceeds from the exercise of stock options and employee stock purchases		27
Payments on finance leases		(386)
Payments on other long-term liabilities		(67)
Net cash provided by financing activities	37,857	13,376
Effect of exchange rate changes on cash and cash equivalents	(487)	(675)
Decrease in cash and cash equivalents	(21,187)	(49,307)
Cash and cash equivalents at beginning of period	143,428	240,229
Cash and cash equivalents at end of period	122,241	190,922
Supplemental disclosure of cash flow information:
Cash paid for interest	3,224	3,292
Non-cash investing and financing activities:
Vesting of restricted stock units	$ 1,763	$ 7,129

Nature of Business

Nature of Business	3 Months Ended
	Mar. 31, 2022
Nature of Business
Nature of Business	CLOVIS ONCOLOGY, INC. ​ NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS ​ 1. Nature of Business ​ Clovis Oncology, Inc. (together with its consolidated subsidiaries, the “Company”, “Clovis”, “we”, “our”, “us”) is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. We target our development programs for the treatment of specific subsets of cancer populations, and simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. We have and intend to continue to license or acquire rights to oncology compounds in all stages of development. In exchange for the right to develop and commercialize these compounds, we generally expect to provide the licensor with a combination of upfront payments, milestone payments and royalties on future sales. In addition, we generally expect to assume the responsibility for future drug development and commercialization costs. We currently operate in two segments. Since inception, our operations have consisted primarily of developing in-licensed compounds, evaluating new product acquisition candidates and general corporate activities and since 2016 we have also marketed and sold products. ​ Our marketed product Rubraca® (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (“PARP”), is marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and also an indication specific to metastatic castration-resistant prostate cancer (“mCRPC”). The initial indication received approval from the United States Food and Drug Administration (“FDA”) in December 2016 and covers the treatment of adult patients with deleterious BRCA ​ In May 2020, the FDA approved Rubraca for the treatment of adult patients with mCRPC associated with a deleterious BRCA ​ In Europe, the European Commission granted a conditional marketing authorization in May 2018 for Rubraca as monotherapy treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA BRCA ​ Beyond our labeled indications, we have a clinical development program underway to further evaluate Rubraca in a variety of solid tumor types, either as monotherapy or in combination with other agents, including the ATHENA Phase 3 study as part of our ongoing clinical collaboration with Bristol Myers Squibb Company (“Bristol Myers Squibb”) to evaluate its immunotherapy OPDIVO® (nivolumab) in combination with Rubraca. ​ On March 31, 2022, we announced positive top-line data from the monotherapy portion of the ATHENA (GOG 3020/ENGOT-ov45) trial (ATHENA-MONO) demonstrating that Rubraca as maintenance treatment successfully achieved the primary endpoint of significantly improved investigator-assessed progression-free survival (“PFS”) compared with placebo. Benefit was observed in both primary efficacy analyses of newly-diagnosed patients with advanced ovarian cancer following successful treatment with platinum-based chemotherapy: those who had homologous recombination deficiency (HRD-positive), including deleterious BRCA BRCA BRCA BRCA BRCA ​ The timing for Phase 3 data readouts from each of TRITON3 and ATHENA-COMBO is contingent upon the occurrence of the protocol-specified PFS events, and timing estimates are based on event-based projections. ​ We hold worldwide rights to Rubraca. ​ FAP-2286 is our initial product candidate to emerge from our targeted radionuclide collaboration with 3B Pharmaceuticals GmbH (“3BP”). FAP-2286 is a peptide-targeted radionuclide therapy (“PTRT”) and imaging agent targeting fibroblast activation protein (“FAP”). PTRT uses cancer cell-targeting peptides to deliver radiation-emitting radionuclides specifically to tumors. Following the clearance by the FDA of two INDs submitted in December 2020 to support the use of FAP-2286 as an imaging and treatment agent, we initiated the phase 1 portion of the LuMIERE clinical study in June 2021. LuMIERE is a phase 1/2 study of FAP-2286 labeled with lutetium-177 ( 177 68 ​ We plan to present phase 1 clinical data from LuMIERE in an oral presentation at the Society of Nuclear Medicine & Molecular Imaging (“SNMMI”) Annual Meeting in June 2022. During 2022, we also anticipate additional presentations of non-clinical data for FAP-2286 and the launch of our combination study program to explore FAP-2286 in combination with other oncology compounds, and in 2023, a potential IND filing of FAP-2286 linked to a FAP-targeted alpha-emitter PTRT. ​ We hold U.S. and global rights to FAP-2286, excluding Europe (defined to include Russia, Turkey and Israel), where 3BP retains rights. We are also collaborating with 3BP on a discovery program directed to up to three additional, undisclosed targets for targeted radionuclide therapy, to which we would have global rights for any resulting product candidates. ​ Lucitanib, our product candidate currently in clinical development, is an investigational, oral, potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors 1 through 3 (“VEGFR1-3”), platelet-derived growth factor receptors alpha and beta (“PDGFR α/β”) and fibroblast growth factor receptors 1 through 3 (“FGFR1-3”). Lucitanib inhibits the same three pathways as Lenvima® (lenvatinib), which has received an FDA approval for use in certain populations of patients with endometrial cancer in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor. This, together with preclinical data for lucitanib in combination with a PD-1 inhibitor that demonstrated enhanced anti-tumor activity compared to that of single agents, represent a scientific rationale for development of lucitanib in combination with a PD-1 inhibitor, and in February 2019, lucitanib was added to our clinical collaboration with Bristol Myers Squibb. The phase 1b/2 LIO-1 study evaluated the combination of lucitanib and Opdivo in gynecologic cancers. Interim data from the non-clear cell ovarian cancer expansion cohort were presented at the American Society of Clinical Oncology (“ASCO”) 2021 and the initial efficacy data do not support further development in non-clear cell ovarian cancer. The remaining three cohorts, which include non-clear cell endometrial, cervical and clear-cell ovarian and endometrial cancers, showed sufficient responses in stage one of each of the cohorts to advance to stage 2. The data from the cervical cohort was presented at the Society of Gynecologic Oncology (“SGO”) 2022 Annual Meeting on Women’s Cancer in March 2022 and represent encouraging data in this subset of gynecological cancers. Phase 2 LIO-1 efficacy and safety data results across the different types of gynecologic cancers will also be presented at the ASCO 2022 Annual Meeting in June. However, given the competing priorities, including development of FAP-2286, we have determined that we will not pursue further development of lucitanib in gynecological cancers at this time. ​ We hold the global (excluding China) development and commercialization rights for lucitanib. ​ Going Concern and Management Plans ​ We have incurred significant net losses since inception and have relied on our ability to fund our operations through debt and equity financings. We expect operating losses and negative cash flows to continue for the foreseeable future even with Rubraca now generating revenues. Rubraca revenues have not been consistent in prior quarters, mainly as a result of the impact of COVID-19 and competition from other products on the market, including the impact on second- line maintenance that may result from an increase in first-line maintenance treatment of ovarian cancer, which has made forecasting revenues difficult. In addition to factors described, future Rubraca revenues will depend, in part, on the timing and extent of any recovery from the impacts of COVID-19, with any such recovery of revenues expected to take several quarters to have a meaningful impact on our financial results. We do not expect to generate a sufficient amount of Rubraca revenues to finance our cash requirements in the foreseeable future, and which we may never be able to do in sufficient amounts. We require significant cash resources to execute our business plans and we will need to raise additional cash to continue to fund our operating plan. We cannot be certain that additional funding will be available on acceptable terms, or at all, especially given that we will need our stockholders to approve an amendment to our certificate of incorporation to increase the number of shares of common stock that we are authorized to issue. The aforementioned factors, which are largely outside of our control, raise substantial doubt about our ability to continue as a going concern within one year from the date of filing of this quarterly report. ​ In the near term, we believe there is some flexibility within our operating plan, particularly with managing certain discretionary expenses, to adjust to variations in our expected Rubraca revenues and the availability and timing of potential sources of financings to meet our working capital requirements. However, based on our current cash, cash equivalents and liquidity available under our ATHENA clinical financing agreement, together with current estimates for revenues generated by sales of Rubraca, we will need to raise additional capital in the near term in order to fund our operating plan for the next 12 months and to continue as a going concern. Our ability to obtain additional financing (including through collaborating and licensing arrangements) will depend on a number of factors, including, among others, our ability to generate positive data from our clinical studies and to obtain label expansions through regulatory approvals, the condition of the capital markets and the other risks described under Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2021 (“2021 Form 10-K”). We expect to finance our operating plan through a combination of public or private equity or debt offerings, collaborations, strategic alliances and other similar licensing arrangements in both the short term and the long term. ​ We currently have capacity to issue approximately $16.5 million of additional shares of common stock under our previously established ATM Program, assuming the remaining authorized but unissued shares of our common stock are sold at an offering price of $2.03 per share, the closing price of our common stock on the Nasdaq Global Select Market on May 2, 2022. There can be no assurance that we will be able to sell any shares of our common stock under the ATM Program or regarding the price at which we will be able to sell any such shares, and any sales of shares of our common stock under the ATM Program may be at prices that result in additional dilution to existing stockholders of the Company. ​ We will not be able to raise sufficient additional capital through public or private equity offerings (or offerings of securities convertible into our equity securities) until our stockholders approve a proposed reverse stock split of our common stock at our 2022 Annual Meeting of Stockholders, which, when implemented by our board of directors, will have the effect of increasing the number of authorized but unissued and unreserved shares of our common stock that are available to be issued. We cannot be certain that our stockholders will approve such a proposal. In the event our stockholders do not approve such a proposal, our ability to raise capital to fund our operations beyond the next 12 months will be significantly limited. ​ In light of the uncertainty about our ability to raise sufficient capital through potential equity offerings (or offerings of securities convertible into equity securities), we are considering other sources of funding, potentially through incurring further indebtedness or entering into strategic partnerships or licensing arrangements for one or more of our products or product candidates in which we may have to give up certain of our future commercialization or other rights to obtain interim funding. We are exploring various partnership and licensing arrangements for our products and product candidates outside the U.S., but those will largely depend on our ability to generate positive data from our clinical studies and to obtain label expansions through regulatory approvals. We cannot be certain that such other sources of funding will be available to us or on acceptable terms or in sufficient amounts to meet our requirements. ​ In the event that we are unable to raise sufficient additional capital, which is dependent on factors outside of our control, we will need to cut expenses further, including potentially delaying, scaling back or eliminating certain of our pipeline development programs, and undertake a more significant restructuring of our operations, in order to continue as a going concern and fund our committed obligations and working capital requirements. There can be no assurances that we will be able to achieve such a restructuring or that such a restructuring will be successful over the long term to allow us to fund our requirements and our plan to invest sufficient amounts to fund the development of FAP-2286 to its potential. ​ Basis of Presentation ​ All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. ​ The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our 2021 Form 10-K for a broader discussion of our business and the opportunities and risks inherent in such business. ​ Use of Estimates ​ The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies ​ Recently Adopted Accounting Standards ​ In August 2020, the FASB issued guidance that simplifies an issuer’s accounting for debt and equity instruments. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted. We adopted this guidance on January 1, 2022 and there was no material impact on our consolidated financial statements and related disclosures. ​ Revenue Recognition ​ We are currently approved to sell Rubraca in the United States and Europe markets. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and health care providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. ​ Product Revenue ​ Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our product at a point in time, typically upon delivery. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less. ​ Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (“transaction price”), which includes estimates of variable consideration for which reserves are established and which result from price concessions that include rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. ​ Government Rebates ​ GPO and Payor Rebates. ​ Chargebacks ​ Discounts and Fees ​ Co-pay assistance Returns product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns based on additional historical experience. ​ Cost of Sales – Product ​ Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. ​ Cost of Sales – Intangible Asset Amortization ​ Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca. ​ Accounts Receivable ​ We provide an allowance for credit losses based on experience and specifically identified risks. Accounts receivable are charged off against the allowance when we determine that recovery is unlikely and we cease collection efforts. ​ Inventory ​ Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out (“FIFO”) basis. Inventories include active pharmaceutical ingredient (“API”), contract manufacturing costs and overhead allocations. We begin capitalizing incurred inventory related costs upon regulatory approval. Prior to regulatory approval, incurred costs for the manufacture of the drugs that could potentially be available to support the commercial launch of our products are recognized as research and development expense. ​ We regularly analyze our inventory levels for excess quantities and obsolescence (expiration), considering factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf-life of Rubraca. Rubraca finished goods have a shelf-life of four years from the date of manufacture. We expect to sell the finished goods prior to expiration. The API currently has a shelf-life of five years from the date of manufacture but can be retested at an immaterial cost with no expected reduction in potency, thereby extending its shelf-life as needed. We expect to consume substantially all of the API over a period of approximately seven years based on our long-range sales projections of Rubraca. ​ We write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements. Expired inventory would be disposed of and the related costs would be written off as cost of product revenue. Inventories that are not expected to be consumed within 12 months following the balance sheet date are classified as long-term inventories. Long-term inventories primarily consist of API. ​ API is currently produced by Lonza. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. In addition, we currently manufacture Rubraca finished goods with a single third-party manufacturer. The disruption or termination of the supply of API or the disruption or termination of the manufacturing of our commercial products could have a material adverse effect on our business, financial position and results of operations. API that is written off due to damage and certain costs related to our production train at Lonza are included in Other Operating Expenses on the Consolidated Statements of Operations and Comprehensive Loss. ​ Inventory used in clinical trials is expensed as research and development expense when it has been identified for such use. ​ Segment Information ​ We have two operating and reportable segments, U.S. and ex-U.S., based on product revenue by geographic areas. We designated our reporting segments based on the internal reporting used by the Chief Operating Decision Maker (“CODM”), which is our Chief Executive Officer, for making decisions and assessing performance as the source of our reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on product revenue by geographic areas. Accordingly, we view our business as two reportable operating segments to evaluate performance, allocate resources, set operational targets and forecast our future period financial results. ​ We manage our assets on a company basis, not by segments, as many of our assets are shared or commingled. Our CODM does not regularly review asset information by reportable segment. The majority of long-lived assets for both segments are located in the United States. ​ Research and Development Expense ​ Research and development costs are charged to expense as incurred and include, but are not limited to, salary and benefits, share-based compensation, clinical trial activities, drug development and manufacturing, companion diagnostic development and third-party service fees, including contract research organizations and investigative sites. ​ Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred and are reflected on the Consolidated Balance Sheets as prepaid or accrued research and development expenses. ​ Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Financial Instruments and Fair Value Measurements
Financial Instruments and Fair Value Measurements	3. Financial Instruments and Fair Value Measurements ​ Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (at exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The three levels of inputs that may be used to measure fair value include: ​ Level 1: Quoted prices in active markets for identical assets or liabilities. Our Level 1 assets consist of money market investments. We do not have Level 1 liabilities. ​ ​ Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. We do not have Level 2 assets or liabilities. ​ ​ Level 3: Unobservable inputs that are supported by little or no market activity. We do not have Level 3 assets or liabilities. ​ The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance Level 1 Level 2 Level 3 March 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market investments ​ $ 72,941 ​ $ 72,941 ​ $ — ​ $ — ​ Total assets at fair value ​ $ 72,941 ​ $ 72,941 ​ $ — ​ $ — ​ December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market investments ​ $ 72,934 ​ $ 72,934 ​ $ — ​ $ — ​ Total assets at fair value ​ $ 72,934 ​ $ 72,934 ​ $ — ​ $ — ​ ​ There were no liabilities that were measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021. ​ Financial instruments not recorded at fair value include our convertible senior notes. At March 31, 2022, the carrying amount of the 2024 Notes (2019 Issuance) was $84.5 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $57.5 million. At March 31, 2022, the carrying amount of the 2024 Notes (2020 Issuance) was $56.9 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $44.0 million. At March 31, 2022, the carrying amount of the 2025 Notes was $295.9 million, which represents the aggregate principal amount net of remaining debt issuance costs, and the fair value was $205.1 million. The fair value was determined using Level 2 inputs based on the indicative pricing published by certain investment banks or trading levels of the convertible senior notes, which are not listed on any securities exchange or quoted on an inter-dealer automated quotation system. See Note 9, Debt

Inventories

Inventories	3 Months Ended
	Mar. 31, 2022
Inventories
Inventories	4. Inventories ​ The following table presents inventories as of March 31, 2022 and December 31, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ 2022 2021 Work-in-process $ 83,462 $ 85,084 Finished goods, net ​ 37,160 ​ 38,452 Total inventories $ 120,622 $ 123,536 ​

Other Current Assets

Other Current Assets	3 Months Ended
	Mar. 31, 2022
Other Current Assets
Other Current Assets	​ 5. Other Current Assets ​ Other current assets were comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2022 2021 Prepaid insurance ​ $ 3,772 ​ $ 794 ​ Prepaid IT ​ ​ 593 ​ ​ 769 ​ Prepaid variable considerations ​ ​ 1,483 ​ ​ 1,336 ​ Prepaid expenses - other ​ 3,474 ​ 1,936 ​ Value-added tax ("VAT") receivable ​ ​ 5,519 ​ ​ 4,307 ​ Receivable - other ​ 1,661 ​ 2,499 ​ Other ​ 64 ​ 65 ​ Total ​ $ 16,566 ​ $ 11,706 ​ ​

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
	Mar. 31, 2022
Intangible Assets and Goodwill
Intangible Assets and Goodwill	6. Intangible Assets and Goodwill ​ Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2022 2021 Intangible asset - milestones ​ $ 79,850 ​ $ 79,850 Accumulated amortization ​ (20,821) ​ (19,479) Total intangible asset, net ​ $ 59,029 ​ $ 60,371 ​ ​ The estimated useful lives of these intangible assets are based on the estimated remaining patent life of Rubraca and extend through 2031 in Europe and 2035 in the U.S. ​ We recorded amortization expense of $1.3 million related to capitalized milestone payments during the three months ended March 31, 2022 and March 31, 2021. Amortization expense is included in cost of sales – intangible asset amortization on the Consolidated Statements of Operations and Comprehensive Loss. ​ Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ 2022 (remaining nine months) ​ ​ ​ ​ $ 4,028 2023 ​ ​ ​ ​ ​ 5,371 2024 ​ ​ ​ ​ ​ 5,371 2025 ​ ​ ​ ​ ​ 5,371 2026 ​ ​ ​ ​ ​ 5,371 Thereafter ​ ​ ​ ​ ​ 33,517 ​ ​ ​ ​ ​ $ 59,029 ​

Other Accrued Expenses

Other Accrued Expenses	3 Months Ended
	Mar. 31, 2022
Other Accrued Expenses
Other Accrued Expenses	7. Other Accrued Expenses ​ Other accrued expenses were comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2022 2021 Accrued personnel costs ​ $ 10,459 ​ $ 15,714 ​ Accrued interest payable for convertible senior notes ​ 2,609 ​ 3,283 ​ Income tax payable ​ ​ 871 ​ ​ 1,579 ​ Accrued corporate legal fees and professional services ​ ​ 185 ​ ​ 141 ​ Accrued royalties ​ ​ 5,226 ​ ​ 5,463 ​ Accrued variable considerations ​ ​ 17,907 ​ ​ 17,211 ​ Accrued legal settlement loss ​ ​ 2,325 ​ ​ 2,325 ​ Accrued expenses - other ​ 5,048 ​ 5,155 ​ Total ​ $ 44,630 ​ $ 50,871 ​ ​

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases
Leases	8. Leases ​ At the inception of an arrangement, we determine whether the arrangement is or contains a lease based on the unique facts and circumstances. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. We elected not to recognize on the balance sheet leases with terms of one year or less. Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. ​ The components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, maintenance, consumables, etc.) and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on fair values assigned to the lease components and non-lease components. ​ Our facilities operating leases have lease components, non-lease components and non-components, which we have separated because the non-lease components and non-components have variable lease payments and are excluded from the measurement of the lease liabilities. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis to the statements of operations. ​ We lease all of our office facilities in the U.S. and Europe. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Most leases include one or more options to renew. The exercise of lease renewal options is at our sole discretion. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. ​ Prior to June 30, 2021, we had a finance lease and operating lease for certain equipment at the production train at Lonza, our non-exclusive manufacturer of the Rubraca API. Pursuant to the terms of Amendment 2 discussed in Note 14, Commitments and Contingencies ​ The components of lease expense and related cash flows were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ Three months ended March 31, ​ 2022 2021 Lease cost ​ ​ ​ ​ ​ ​ Finance lease cost: ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ $ — ​ $ 474 Interest on lease liabilities ​ — ​ 185 Operating lease cost ​ 1,215 ​ 1,253 Short-term lease cost ​ 77 ​ 80 Variable lease cost ​ ​ 639 ​ ​ 523 Total lease cost ​ $ 1,931 ​ $ 2,515 ​ ​ ​ ​ ​ ​ ​ Operating cash flows from finance leases ​ $ — ​ $ 185 Operating cash flows from operating leases ​ $ 1,215 ​ $ 1,253 Financing cash flows from finance leases ​ $ — ​ $ 386 ​ The weighted-average remaining lease term and weighted-average discount rate were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 March 31, 2021 ​ Weighted-average remaining lease term (years) ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 5.6 ​ ​ 6.4 ​ Finance leases ​ ​ N/A ​ ​ 4.8 ​ Weighted-average discount rate ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 8% ​ ​ 8% ​ Finance leases ​ ​ N/A ​ ​ 8% ​ ​ Future minimum commitments due under these lease agreements as of March 31, 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ ​ 2022 (remaining nine months) ​ 4,076 ​ 2023 ​ 4,906 ​ 2024 ​ 4,650 ​ 2025 ​ ​ 4,805 ​ ​ 2026 ​ ​ 4,934 ​ ​ Thereafter ​ 4,899 ​ Present value adjustment ​ ​ (5,710) ​ ​ Present value of lease payments ​ $ 22,560 ​ ​ ​

Debt

Debt	3 Months Ended
	Mar. 31, 2022
Debt
Debt	9. Debt ​ The following is a summary of our convertible senior notes at March 31, 2022 and December 31, 2021 (principal amount in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Principal Amount ​ Principal Amount ​ ​ ​ ​ ​ Conversion rate per $1,000 ​ ​ March 31, 2022 ​ December 31, 2021 ​ Interest Rate ​ Maturity Date ​ principal amount (shares) 2024 Notes (2019 Issuance) ​ 85,782 ​ 85,782 ​ 4.50% ​ August 1, 2024 ​ 137.2213 2024 Notes (2020 Issuance) ​ ​ 57,500 ​ ​ 57,500 ​ 4.50% ​ August 1, 2024 ​ 160.3334 2025 Notes ​ 300,000 ​ 300,000 ​ 1.25% ​ May 1, 2025 ​ 13.1278 Total ​ ​ 443,282 ​ ​ 443,282 ​ ​ ​ ​ ​ ​ Unamortized debt issuance costs ​ ​ (5,998) ​ ​ (6,510) ​ ​ ​ ​ ​ ​ Convertible senior notes ​ $ 437,284 ​ $ 436,772 ​ ​ ​ ​ ​ ​ ​ Our convertible senior notes are governed by the terms of their respective indentures between the Company, as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee. Holders may convert all or any portion of the senior notes at any time prior to the close of business on the business day immediately preceding the maturity date. Upon conversion, the holders will receive shares of our common stock at an initial conversion rate as noted above. The conversion rate is subject to adjustment upon the occurrence of certain events described in the indentures. ​ If we undergo a fundamental change, as defined in the indenture, prior to the maturity date of the senior notes, holders may require us to repurchase for cash all or any portion of the senior notes at a fundamental change repurchase price equal to 100% of the principal amount of the senior notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date. ​ The senior notes rank senior in right of payment to any of our indebtedness that is expressly subordinated in right of payment to the senior notes; equal in right of payment to all of our liabilities that are not so subordinated; effectively junior in right of payment to any secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables) of our subsidiaries. ​ The debt issuance costs are presented as a deduction from the convertible senior notes on the Consolidated Balance Sheets and are amortized as interest expense over the expected life of the convertible senior notes using the effective interest method. ​ Maturities of our convertible notes consisted of the following as of March 31, 2022 (in thousands): ​ ​ ​ ​ ​ 2022 (remaining nine months) ​ $ — 2023 ​ ​ — 2024 ​ ​ 143,282 2025 ​ ​ 300,000 2026 ​ ​ — Thereafter ​ ​ — ​ ​ ​ 443,282 Less debt issuance costs ​ ​ (5,998) Current portion ​ ​ — Long-term portion ​ $ 437,284 ​ Sixth Street Financing Agreement ​ On May 1, 2019, we entered into a financing agreement (the “Financing Agreement”) with certain affiliates of Sixth Street Partners, LLC (“Sixth Street”) in which we plan to borrow from Sixth Street amounts required to reimburse our actual costs and expenses incurred during each fiscal quarter (limited to agreed budgeted amounts), as such expenses are incurred, related to the ATHENA clinical trial, in an aggregate amount of up to $175 million (the amount actually borrowed, the “Borrowed Amount”). ATHENA is our largest clinical trial, with a target enrollment of 1,000 patients across more than 270 sites in at least 25 countries. The Clovis-sponsored phase 3 ATHENA study in advanced ovarian cancer is in the first-line maintenance treatment setting evaluating Rubraca plus nivolumab (PD-1 inhibitor), Rubraca, nivolumab and a placebo in newly-diagnosed patients who have completed platinum-based chemotherapy. This study initiated in the second quarter of 2018 completed enrollment during the second quarter of 2020, and top-line data from the ATHENA-MONO study was announced during the first quarter of 2022. Top-line data readout from the ATHENA-COMBO study is anticipated in the first quarter of 2023, contingent upon the occurrence of the protocol-specified PFS events. ​ We incur borrowings under the Financing Agreement on a quarterly basis, beginning with such expenses incurred during the quarter ended March 31, 2019 and ending generally on the earliest to occur of (i) the termination of the ATHENA Trial, (ii) the date of completion of all activities under the ATHENA Trial Clinical Study Protocol, (iii) the date on which we pay the Discharge Amount (as defined in the Financing Agreement), (iv) the date of the occurrence of a change of control of us (or a sale of all or substantially all of our assets related to Rubraca) or our receipt of notice of certain breaches by us of our obligations under material in-license agreements related to Rubraca and (v) September 30, 2022. ​ We are obligated to repay on a quarterly basis, 30 days after the end of the quarter, beginning on the earliest to occur of (i) the termination of the ATHENA Trial, (ii) the approval by the FDA of an update to the label portion of the Rubraca new drug application (“NDA”) to include in such label the treatment of an indication resulting from the ATHENA Trial, (iii) the date on which we determine that the results of the ATHENA Trial are insufficient to achieve such an expansion of the Rubraca label to cover an indication based on the ATHENA Trial and (iv) September 30, 2022 (the “Repayment Start Date”). We expect to make the first payment by October 30, 2022, unless one of the other events occurs prior to September 30, 2022. ​ ● 9.75% (which rate may be increased incrementally up to approximately 10.25% in the event the Borrowed Amount exceeds $166.5 million) of the direct Rubraca net sales recorded by us and our subsidiaries worldwide and our future out-licensees in the United States, if any, during such quarter; ​ ● 19.5% of any royalty payments received by us and our subsidiaries during such quarter based on the sales of Rubraca by our future out-licensees outside the United States, if any; and ​ ● 19.5% of any other amounts received by us and our subsidiaries in connection with any other commercialization arrangement for Rubraca, including any upfront and milestone payments and proceeds of infringement claims (which payments are not subject to the caps described below). ​ Quarterly payments are capped at $8.5 million, unless the label portion of the Rubraca NDA is expanded by the FDA to include on such label the treatment of an indication resulting from the ATHENA Trial, in which case the quarterly payment is capped at $13.5 million. In the event the aggregate Borrowed Amount exceeds $166.5 million, such quarterly limits will be incrementally increased to a maximum of approximately $8.9 million and $14.2 million, respectively. The maximum amount required to be repaid under the agreement is two times the aggregate Borrowed Amount, which may be $350 million in the event we borrow the full $175 million under the Financing Agreement. Quarterly payments are due within 30 days after each calendar quarter. Our first quarterly payment is estimated to be due on October 30, 2022, 30 days after the Repayment Start Date. ​ In the event we have not made payments on or before December 30, 2025 equal to at least the Borrowed Amount, we are required to make a lump sum payment in an amount equal to such Borrowed Amount less the aggregate of all prior quarterly payments described above. All other payments are contingent on the performance of Rubraca. There is no final maturity date on the Financing Agreement. ​ Our obligations under the Financing Agreement are secured under a Pledge and Security agreement by a first priority security interest in all of our assets related to Rubraca, including intellectual property rights and a pledge of the equity of our wholly owned subsidiaries, Clovis Oncology UK Limited and Clovis Oncology Ireland Limited. In addition, the obligations are guaranteed by Clovis Oncology UK Limited and Clovis Oncology Ireland Limited, secured by a first priority security interest in all the assets of those subsidiaries. ​ Pursuant to the Financing Agreement, we have agreed to certain limitations on our operations, including limitations on making certain restricted junior payments, including payment of dividends, limitation on liens and certain limitations on the ability of our non-guarantor subsidiaries to own certain assets related to Rubraca and to incur indebtedness. ​ We may terminate the Financing Agreement at any time by paying the lenders an amount (the “Discharge Amount”) equal to the sum of (a) (A) (i) if such date is prior to the Repayment Start Date, 1.75 times the Borrowed Amount or (ii) if such date is after the Repayment Start Date, 2.00 times the Borrowed Amount minus (B) the aggregate amount of all quarterly payments previously paid to the lenders plus (b) all other obligations which have accrued but which have not been paid under the loan documents, including expense reimbursement. ​ In the event of (i) a change of control of us, we must pay the Discharge Amount to the lenders and (ii) an event of default under the Financing Agreement (which includes, among other events, breaches or defaults under or terminations of our material in-license agreements related to Rubraca and defaults under our other material indebtedness), the lenders have the right to declare the Discharge Amount to be immediately due and payable. ​ If an event of default were to occur under the Financing Agreement, or if an event of default were to be determined to be probable, we would classify all our obligations that become due and payable thereunder as current liabilities. ​ For the three months ended March 31, 2022, we used an effective interest rate of 13.7%, which is based on the estimate of remaining cash flows. For subsequent periods, we will use the prospective method whereby a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize interest expense for the remaining periods. Under this method, the effective interest rate is not constant, and any change in expected cash flows is recognized prospectively as an adjustment to the effective yield. ​ Amounts reflected on the balance sheet and in the table below in respect of the Financing Agreement represent the maximum amounts payable by us to the lenders during the periods indicated. Payments due under our Financing Agreement are based, for the most part, on net sales of Rubraca by us and our licensees. Rubraca sales have not been consistent historically and sales in future periods are difficult to predict. Therefore, expected maturities of our Financing Agreement as of March 31, 2022 (in thousands) are shown below based on the quarterly capped amount described above and certain other mandatory payments set forth in the Financing Agreement. Actual payments may fluctuate and may be less than the amounts reflected in the table below. See above for a full description of the Financing Agreement and our payment obligations thereunder. ​ ​ ​ ​ ​ 2022 (remaining nine months) ​ $ 8,500 2023 ​ ​ 34,000 2024 ​ ​ 34,000 2025 ​ ​ 79,939 2026 ​ ​ 34,000 Thereafter ​ ​ 122,438 ​ ​ ​ 312,877 Less debt issuance costs ​ ​ (1,232) Less unrecognized interest ​ ​ (117,930) Current portion ​ ​ (17,000) Long-term portion ​ $ 176,715 ​ The following table sets forth total interest expense recognized during the three months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ 2022 2021 Interest on convertible notes ​ $ 2,549 ​ $ 2,977 ​ Amortization of debt issuance costs ​ 558 ​ 639 ​ Interest on finance lease ​ ​ — ​ ​ 185 ​ Interest on borrowings under financing agreement ​ ​ 5,993 ​ ​ 4,210 ​ Other interest ​ ​ — ​ ​ 26 ​ Total interest expense ​ $ 9,100 ​ $ 8,037 ​ ​

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity
Stockholders' Equity	10. Stockholders’ Equity ​ Common Stock ​ The holders of common stock are entitled to one vote per share on all matters to be voted upon by our stockholders. Subject to the preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors. ​ On May 17, 2021, we entered into a distribution agreement (the “Distribution Agreement”) with J.P. Morgan Securities LLC and BofA Securities, Inc., as agents (the “Agents”), pursuant to which we may offer and sell, from time to time, through the Agents, shares of our common stock having an aggregate offering price of up to $75.0 million in transactions that are deemed to be “at the market” offerings as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including directly on the Nasdaq Global Select Market or into any other existing trading market for the Shares, or sales made to or through a market maker, in block transactions or by any other method permitted by law, including negotiated transactions. Sales may be made at market prices prevailing at the time of a sale or at prices related to prevailing market prices or at negotiated prices. During the period between May 18, 2021 and June 9, 2021, we sold an aggregate of 13,492,231 shares of our common stock under the Distribution Agreement resulting gross proceeds of $75.0 million and net proceeds to us of $72.5 million, after deducting commissions and offering expenses, effectively closing out sales we may make pursuant to the Distribution Agreement. We have used and intend to use the net proceeds of this offering for general corporate purposes, including funding of our development programs, sales and marketing expenses associated with Rubraca, repayment, repurchase or refinance of our debt obligations, payment of milestones pursuant to our license agreements, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. ​ On August 16, 2021, we entered into a distribution agreement (the “August Distribution Agreement”) with the Agents, pursuant to which we may offer and sell, from time to time, through the Agents, shares of our common stock, having an aggregate offering price of up to $125.0 million in transactions that are deemed to be “at the market” offerings as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including sales made by means of ordinary brokers’ transactions, including directly on the Nasdaq Global Select Market or into any other existing trading market for the shares, or sales made to or through a market maker, in block transactions or by any other method permitted by law, including privately negotiated transactions. Sales may be made at market prices prevailing at the time of a sale or at prices related to prevailing market prices or at negotiated prices. During the period between August 17, 2021 and September 15, 2021, we sold an aggregate of 9,379,976 shares of our common stock under the August Distribution Agreement resulting in gross proceeds of $43.0 million and net proceeds to us of $41.5 million, after deducting commissions and offering expenses. During the period between November 5, 2021 and November 16, 2021, we sold an aggregate of 731,292 shares of our common stock resulting in gross proceeds of $3.1 million and net proceeds to us of $3.0 million, after deducting commissions and offering expenses. ​ During the period between January 18, 2022 and March 3, 2022, we sold an aggregate of 13,870,410 shares of our common stock resulting in gross proceeds of $29.8 million and net proceeds to us of $28.6 million, after deducting commissions and offering expenses. ​ We have used and intend to use the net proceeds of this offering for general corporate purposes, including funding of our development programs, sales and marketing expenses associated with Rubraca, repayment, repurchase or refinance of our debt obligations, payment of milestones pursuant to our license agreements, general and administrative expenses, acquisition or licensing of additional product candidates or businesses and working capital. ​ Accumulated Other Comprehensive Loss ​ Accumulated other comprehensive loss consists of changes in foreign currency translation adjustments, which includes changes in a subsidiary’s functional currency, and unrealized gains and losses on available-for-sale securities. ​ The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended March 31, 2022 and 2021, as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign Currency ​ Unrealized ​ Total Accumulated ​ ​ Translation Adjustments ​ Losses ​ Other Comprehensive Loss ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ Balance at Jan 1, ​ $ (43,291) ​ $ (44,165) ​ $ (139) ​ $ (139) ​ $ (43,430) ​ $ (44,304) ​ Other comprehensive income ​ ​ 435 ​ ​ (80) ​ ​ — ​ ​ — ​ ​ 435 ​ ​ (80) ​ Total before tax ​ ​ (42,856) ​ ​ (44,245) ​ ​ (139) ​ ​ (139) ​ ​ (42,995) ​ ​ (44,384) ​ Tax effect ​ — ​ ​ — ​ — ​ ​ — ​ — ​ ​ — ​ Balance at March 31, ​ $ (42,856) ​ $ (44,245) ​ $ (139) ​ $ (139) ​ $ (42,995) ​ $ (44,384) ​ ​ There were no reclassifications out of accumulated other comprehensive loss in each of the three months ended March 30, 2022 and 2021.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-Based Compensation
Share-Based Compensation	11. Share-Based Compensation ​ Share-based compensation expense for all equity-based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three months ended March 31, 2022 and 2021 was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ 2022 2021 Research and development ​ $ 3,229 ​ $ 2,876 ​ ​ Selling, general and administrative ​ 3,403 ​ 1,163 ​ ​ Total share-based compensation expense ​ $ 6,632 ​ $ 4,039 ​ ​ ​ We did not recognize a tax benefit related to share-based compensation expense during the three months ended March 31, 2022 and 2021, as we maintain net operating loss carryforwards and have established a valuation allowance against the entire net deferred tax asset as of March 31, 2022 and 2021. ​ Stock Options ​ The following table summarizes the activity relating to our options to purchase common stock for the three months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ Aggregate ​ ​ ​ ​ Average ​ Remaining ​ Intrinsic ​ ​ Number of ​ Exercise ​ Contractual ​ Value ​ ​ Options ​ Price ​ Term (Years) ​ (Thousands) Outstanding at December 31, 2021 ​ 7,010,039 ​ $ 33.36 ​ ​ Granted ​ 516,250 ​ ​ 1.96 ​ ​ Exercised ​ — ​ ​ — ​ ​ Forfeited ​ (342,217) ​ ​ 26.30 ​ ​ Outstanding at March 31, 2022 ​ 7,184,072 ​ $ 31.44 5.7 ​ $ 35 ​ Vested and expected to vest at March 31, 2022 ​ 6,963,967 ​ $ 32.29 5.6 ​ $ 28 ​ Vested and exercisable at March 31, 2022 ​ 5,384,051 ​ $ 39.88 4.6 ​ $ — ​ ​ The aggregate intrinsic value in the table above represents the pretax intrinsic value, based on our closing stock price of $2.02 as of March 31, 2022, which would have been received by the option holders had all option holders with in-the-money options exercised their options as of that date. ​ The following table summarizes information about our stock options as of and for the three months ended March 31, 2022 and 2021 (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ 2022 2021 Weighted-average grant date fair value per share ​ $ 1.47 ​ $ 4.94 ​ Intrinsic value of options exercised ​ $ — ​ $ 14 ​ Cash received from stock option exercises ​ $ — ​ $ 27 ​ ​ As of March 31, 2022, the unrecognized share-based compensation expense related to unvested options, adjusted for expected forfeitures, was $6.2 million and the estimated weighted-average remaining vesting period was 1.7 years. ​ Restricted Stock ​ The following table summarizes the activity relating to our unvested restricted stock units (“RSUs”) for the three months ended March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ Number of ​ Grant Date ​ ​ Units ​ Fair Value Unvested at December 31, 2021 ​ 3,683,422 ​ $ 8.36 ​ Granted ​ 2,749,649 ​ 1.95 ​ Vested ​ (889,273) ​ 8.43 ​ Forfeited ​ (70,411) ​ 6.96 ​ Unvested at March 31, 2022 ​ 5,473,387 ​ $ 5.15 ​ Expected to vest after March 31, 2022 ​ 4,537,263 ​ $ 5.47 ​ ​ As of March 31, 2022, the unrecognized share-based compensation expense related to unvested RSUs, adjusted for expected forfeitures, was $25.6 million and the estimated weighted-average remaining vesting period was 2.0 years.

License Agreements

License Agreements	3 Months Ended
	Mar. 31, 2022
License Agreements
License Agreements	12. License Agreements ​ Rucaparib ​ In June 2011, we entered into a license agreement with Pfizer, Inc. (“Pfizer”) to obtain the exclusive global rights to develop and commercialize Rubraca. The exclusive rights are exclusive even as to Pfizer and include the right to grant sublicenses. Pursuant to the terms of the license agreement, we made a $7.0 million upfront payment to Pfizer and are required to make additional payments to Pfizer for the achievement of certain development and regulatory and sales milestones and royalties on sales as required by the license agreement. Prior to the FDA approval of Rubraca, we made milestone payments of $1.4 million, which were recognized as acquired in-process research and development expense. ​ During 2016 through 2020, we paid Pfizer a total of $82.5 million in milestone payments related to the FDA and European Commission approvals received for Rubraca. These milestone payments were recognized as intangible assets and are amortized over the estimated remaining useful life of Rubraca. ​ We are obligated under the license agreement to use commercially reasonable efforts to develop and commercialize Rubraca and we are responsible for all ongoing development and commercialization costs for Rubraca. We are required to make regulatory milestone payments to Pfizer of up to an additional $8.0 million in aggregate if specified clinical study objectives and regulatory filings, acceptances and approvals are achieved. In addition, we are obligated to make sales milestone payments to Pfizer if specified annual sales targets for Rubraca are met, which relate to annual sales targets of $250.0 million and above, which, in the aggregate, could amount to total milestone payments of $170.0 million, and tiered royalty payments at a mid-teen percentage rate on net sales, with standard provisions for royalty offsets to the extent we need to obtain any rights from third parties to commercialize Rubraca. ​ The license agreement with Pfizer will remain in effect until the expiration of all of our royalty and sublicense revenue obligations to Pfizer, determined on a product-by-product and country-by-country basis, unless we elect to terminate the license agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Pfizer can terminate the agreement, resulting in a loss of our rights to Rubraca and an obligation to assign or license to Pfizer any intellectual property rights or other rights we may have in Rubraca, including our regulatory filings, regulatory approvals, patents and trademarks for Rubraca. ​ In April 2012, we entered into a license agreement with AstraZeneca to acquire exclusive rights associated with Rubraca under a family of patents and patent applications that claim methods of treating patients with PARP inhibitors in certain indications. The license enables the development and commercialization of Rubraca for the uses claimed by these patents. AstraZeneca also receives royalties on net sales of Rubraca. ​ FAP-2286 and the R adionuclide Therapy Development Program ​ In September 2019, we entered into a global license and collaboration agreement with 3BP to develop and commercialize a PTRT and imaging agent targeting FAP. The lead candidate, designated internally as FAP-2286, is being developed pursuant to a global development plan agreed to by the parties. We are responsible for the costs of all preclinical and clinical development activities described in the plan, including the costs for a limited number of 3BP full-time equivalents and external costs incurred during the preclinical development phase of the collaboration. Upon the signing of the license and collaboration agreement in September 2019, we made a $9.4 million upfront payment to 3BP, which we recognized as acquired in-process research and development expense. ​ Pursuant to the terms of the FAP agreement, we are required to make additional payments to 3BP for annual technology access fees and upon the achievement of certain development and regulatory milestone events (or on certain dates, whichever occur earlier). We are also obligated to pay 3BP single- to low-double-digit royalties on net sales of the FAP-targeted therapeutic product and imaging agent, based on the volume of annual net sales achieved. In addition, 3BP is entitled to receive 34% of any consideration, excluding royalties on the therapeutic product, pursuant to any sublicenses we may grant. ​ We are obligated under the license and collaboration agreement to use diligent efforts to develop FAP-2286 and commercialize a FAP-targeted therapeutic product and imaging agent, and we are responsible for all commercialization costs in our territory. The agreement with 3BP will remain in effect until the expiration of our royalty obligations to 3BP, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, 3BP can terminate the agreement, resulting in a loss of our rights. 3BP also has the right to terminate the agreement under certain circumstances in connection with our change of control in which the acquiring party retains a product competitive with the FAP-targeted therapeutic product or, in the event marketing authorization has not yet been obtained, does not agree to the then-current global development plan. ​ We submitted two INDs for FAP-2286 for use as imaging and treatment agents in December 2020 to support an initial phase 1 study to determine the dose and tolerability of FAP-2286 as a therapeutic agent with expansion cohorts planned in multiple tumor types as part of a global development program. In April 2021, we made a milestone payment to 3BP under the license and collaboration agreement of $2.2 million as a result of the FDA’s acceptance of the IND for the treatment agent. In September 2021, we made a $3.3 million milestone payment to 3BP under the license and collaboration agreement. ​ In February 2020, we finalized the terms of a drug discovery collaboration agreement with 3BP to identify up to three additional, undisclosed targets for PTRT, to which we will obtain global rights for any resulting product candidates. We are responsible for the costs of all preclinical and clinical development activities conducted under the discovery program, including the costs for a limited number of 3BP full-time equivalents and external costs incurred during the discovery and preclinical development phase for each collaboration target. The discovery collaboration agreement was effective December 31, 2019, for which we incurred a $2.1 million technology access fee, which we accrued and recognized as a research and development expense. ​ Pursuant to the terms of the discovery collaboration agreement, we are required to make additional payments to 3BP for annual technology access fees and upon the achievement of certain development and regulatory milestone events (or on certain dates, whichever occur earlier). We are also obligated to pay 3BP a 6% royalty on net sales of License Products (as defined in the agreement), based on the volume of quarterly net sales achieved. ​ We are obligated under the discovery collaboration agreement to use diligent efforts to develop and commercialize the product candidates, if any, that result from the discovery program, and we are responsible for all clinical development and commercialization costs. The agreement with 3BP will remain in effect until the expiration of our royalty obligations to 3BP, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, 3BP can terminate the agreement, resulting in a loss of our rights. ​ Lucitanib ​ On November 19, 2013, we acquired all of the issued and outstanding capital stock of EOS pursuant to the terms set forth in that certain Stock Purchase Agreement, dated as of November 19, 2013 (the “Stock Purchase Agreement”), by and among the Company, EOS, its shareholders (the “Sellers”) and Sofinnova Capital V FCPR, acting in its capacity as the Sellers’ representative. Following the acquisition, EOS became a wholly-owned subsidiary of the Company. Under the terms of the Stock Purchase Agreement, in addition to the initial purchase price paid at the time of the closing of the acquisition and other license fees due to Advenchen described below, we will also be obligated to pay to the Sellers a milestone payment of $65.0 million upon obtaining the first NDA approval from the FDA with respect to lucitanib. ​ In October 2008, Ethical Oncology Science, S.p.A. (“EOS”) (now known as Clovis Oncology Italy Srl) entered into an exclusive license agreement with Advenchen Laboratories LLC (“Advenchen”) to develop and commercialize lucitanib on a global basis, excluding China. We are obligated to pay Advenchen tiered royalties at percentage rates in the mid-single digits on net sales of lucitanib, based on the volume of annual net sales achieved. In addition, after giving effect to the first and second amendments to the license agreement, we are required to pay to Advenchen 25% of any consideration, excluding royalties, we receive from sublicensees, in lieu of the milestone obligations set forth in the agreement. We are obligated under the agreement to use commercially reasonable efforts to develop and commercialize at least one product containing lucitanib, and we are also responsible for all remaining development and commercialization costs for lucitanib. The license agreement with Advenchen will remain in effect until the expiration of all of our royalty obligations to Advenchen, determined on a product-by-product and country-by-country basis, unless we elect to terminate the agreement earlier. If we fail to meet our obligations under the agreement and are unable to cure such failure within specified time periods, Advenchen can terminate the agreement, resulting in a loss of our rights to lucitanib. ​

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2022
Net Loss Per Common Share
Net Loss Per Common Share	13. Net Loss Per Common Share ​ Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the convertible senior notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share. ​ The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ 2022 2021 Common shares under stock incentive plans ​ 5,971 ​ 5,719 ​ Convertible senior notes ​ 24,928 ​ 25,969 ​ Total potential dilutive shares ​ 30,899 ​ 31,688 ​ ​

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies
Commitments and Contingencies	14. Commitments and Contingencies ​ Royalty and License Fee Commitments ​ We have entered into certain license agreements, as identified in Note 12, License Agreements of pre-established development, regulatory and commercial targets. Our payment obligation related to these license agreements is contingent upon the successful development, regulatory approval and commercialization of the licensed products. Due to the nature of these arrangements, the future potential payments are inherently uncertain, and accordingly, we only recognize payment obligations which are probable and estimable as of the balance sheet date. ​ Manufacture and Services Agreement Commitments ​ On October 3, 2016, we entered into a Manufacturing and Services Agreement (the “Agreement”) with a non-exclusive third-party supplier for the production of the active ingredient for Rubraca. Under the terms of the Agreement, we will provide the third-party supplier a rolling forecast for the supply of the active ingredient in Rubraca that will be updated by us on a quarterly basis. We are obligated to order material sufficient to satisfy an initial quantity specified in a forecast. In addition, the third-party supplier has constructed, in its existing facility, a production train that will manufacture the Rubraca active ingredient. We made scheduled capital program fee payments toward capital equipment and other costs associated with the construction of the production train. Beginning in the fourth quarter of 2018, once the facility was operational, we were obligated to pay a fixed facility fee each quarter for the duration of the Agreement, which expires on December 31, 2025, unless extended by mutual consent of the parties. As of March 31, 2022, $39.6 million of purchase commitments remain under the Agreement. ​ At the time we entered into the Agreement, we evaluated the Agreement as a whole and bifurcated into lease and non-lease components, which consisted of an operating lease of warehouse space, financial lease of equipment, purchase of leasehold improvements and prepaid manufacturing costs based upon the relative fair values of each of the deliverables. During October 2018, the production train was placed into service and we recorded the various components of the Agreement. ​ On June 16, 2021, we entered into amendment no. 2 of the Agreement with Lonza (“Amendment 2”). Pursuant to the terms of Amendment 2, we paid Lonza $1.1 million to repurpose the production train so that Lonza will be able to use the facility to manufacture other products for third parties in addition to API for Clovis. Lonza is guaranteeing a minimum percentage usage of this production train for third parties and Lonza would reduce our fixed facility fee starting in 2023 based on this minimum percentage usage. If Lonza is able to utilize greater than the minimum guaranteed percentage, it will increase the reduction to our fixed facility fee. We evaluated Amendment 2 and determined that we no longer have a lease with Lonza at June 30, 2021 because Amendment 2 modified the terms of the Agreement in that Lonza will use a portion of the production train for third parties. The Agreement no longer conveys the right to direct the use of the identified asset and Clovis no longer has the right to obtain substantially all the economic benefit from the asset. As a result, the arrangement is no longer in scope of ​ Legal Proceedings ​ We and certain of our officers were named as defendants in several lawsuits, as described below. We cannot reasonably predict the outcome of these legal proceedings, nor can we estimate the amount of loss or range of loss, if any, that may result. An adverse outcome in these proceedings could have a material adverse effect on our results of operations, cash flows or financial condition. ​ Rociletinib-Related Litigation ​ In March 2017, two putative shareholders of the Company, Macalinao and McKenry (“ Plaintiffs”), filed shareholder derivative complaints against certain directors and officers of the Company in the Court of Chancery of the State of Delaware. On May 4, 2017, the Macalinao and McKenry actions were consolidated for all purposes in a single proceeding under the caption In re Clovis Oncology, Inc. Derivative Litigation On May 18, 2017, Plaintiffs filed a Consolidated Verified Shareholder Derivative Complaint (the “Consolidated Derivative Complaint”). The Consolidated Derivative Complaint generally alleged that the defendants breached their fiduciary duties owed to the Company by allegedly causing or allowing misrepresentations of the Company’s business operations and prospects, failing to ensure that the TIGER-X clinical trial for rociletinib was being conducted in accordance with applicable rules, regulations and protocols, and engaging in insider trading. The Consolidated Derivative Complaint sought, among other things, an award of money damages. On July 31, 2017, the defendants filed a motion to dismiss the Consolidated Derivative Complaint. Plaintiffs filed an opposition to the motion to dismiss on August 31, 2017, and the defendants filed a reply in further support of the motion to dismiss on September 26, 2017. Following supplementation of the complaint by Plaintiffs (the “Supplemental Derivative Complaint”) and additional briefing, the Court held oral arguments on the motion to dismiss on June 19, 2019. ​ On October 1, 2019, Vice Chancellor Joseph R. Slights III of the Delaware Chancery Court, issued a Memorandum Opinion granting in part and denying in part defendants’ motions to dismiss. The Supplemental Derivative Complaint was dismissed as to Plaintiffs’ derivative claims for unjust enrichment and insider trading. The Court allowed Plaintiffs’ remaining derivative claim for breach of fiduciary duty to proceed. ​ On December 17, 2019, the parties participated in a mediation, which did not result in a settlement. On December 22, 2019, the Company’s Board of Directors formed a Special Litigation Committee (the “SLC”) to conduct an investigation of the claims asserted in the Supplemental Derivative Complaint. On February 18, 2020, the SLC moved to stay all proceedings in the Consolidated Derivative Action pending completion of its investigation. Plaintiffs filed their opposition to the motion to stay on March 3, 2020 and the SLC filed its reply on March 13, 2020. On May 12, 2020, after hearing oral argument, Vice Chancellor Slights granted the SLC’s motion to stay proceedings until September 18, 2020 so that the SLC may complete its investigation. Pursuant to subsequent requests by the parties, Vice Chancellor Slights ultimately granted extensions of the stay through and until December 15, 2020. ​ On December 16, 2020, the SLC filed a report (the “SLC Report”) containing the findings of its investigation. The SLC Report concludes that the claims asserted in the Consolidated Derivative Action lack merit. Specifically, the SLC Report finds that the defendants did not breach their fiduciary duties in connection with the Company’s TIGER-X clinical trial. Accordingly, on the same date that the SLC Report was filed, the SLC filed a motion to terminate the Consolidated Derivative Action in Delaware Chancery Court. ​ Following certain discovery on January 7, 2022, the Plaintiffs, the Company and the SLC participated in a mediation, which resulted in the parties reaching an agreement in principle to settle the pending litigation. While the defendants continue to dispute the allegations, on March 4, 2022, the parties executed a stipulation and agreement of settlement to fully resolve the Consolidated Derivative Action without admitting any liability. The settlement is subject to, among other things, approval by the Court. As part of the settlement, the Company agreed to adopt certain corporate governance reforms, including, among other things, the election of one new independent director to the Clovis Board of Directors by the 2023 Annual Meeting of Stockholders and the creation of a management-level Disclosure Committee. Neither the Company nor any of the defendants would make a financial contribution towards the principal terms of the settlement. Moreover, under the terms of the agreement in principle, the Company agreed not to oppose or object to Plaintiffs’ application for an award of attorneys’ fees and expenses not to exceed $2.325 million in the aggregate, which amount, as ultimately awarded by the Court, is payable by the Company and included in Other accrued expenses on the Consolidated Balance Sheets at March 31, 2022 and December 31, 2021. ​ On April 13, 2022, the SLC filed a brief in support of the settlement and Plaintiffs filed their opening brief in support of the settlement and award for attorneys’ fees and expenses. Pursuant to the Scheduling Order entered on March 10, 2022, any objections to the settlement were due on or before April 20, 2022, and no objections were received. On May 4, 2022, after a final hearing, the Delaware Chancery Court entered an order and final judgment approving the settlement. The judgment found that notice to the Company’s stockholders was adequate and sufficient, that the settlement is fair, reasonable and adequate in all respects, and releases claims on behalf of the Company’s stockholders that were brought or could have been brought in the Consolidated Derivative Action and forever bars and enjoins them from prosecuting such claims. ​ European Patent Opposition ​ Two European patents in the rucaparib camsylate salt/polymorph patent family (European Patent 2534153 and its divisional European Patent 3150610) were opposed. In particular, opposition notices against European Patent 2534153 were filed by two parties on June 20, 2017. During an oral hearing that took place on December 4, 2018, the European Patent Office’s Opposition Division maintained European Patent 2534153 in amended and narrowed form with claims to certain crystalline forms of rucaparib camsylate, including, but not limited to, rucaparib S-camsylate Form A, the crystalline form in Rubraca. Clovis and one opponent, Hexal AG, appealed the written decision of the European Opposition Division and filed reply appeal briefs in November 2019. An oral hearing in the appeal is scheduled on December 8, 2022. ​ An opposition against European Patent 3150610 was filed by Generics (UK) Limited on April 30, 2020 on grounds similar to those raised in the opposition notices against European Patent 2534153, which grounds are common in such proceedings. Clovis responded to the opposition notice in European Patent 3150610 by amending the claims to be directed to the use of rucaparib maleate in a method of inhibiting PARP activity or treating cancer. That is, the amended claims do not cover Rubraca. During an oral hearing that took place on November 18, 2021, European Patent 3150610 was revoked and the written decision of the European Patent Office was dated December 15, 2021. Clovis filed its appeal on April 20, 2022. During the appeal, the effect of the Opposition Division’s decision is suspended, and the patent remains in force until a Technical Board of Appeals issues its own decision. ​ In Europe, regulatory exclusivity is available for ten years, plus one year for a new indication; therefore, we have regulatory exclusivity for Rubraca, including all forms of rucaparib, in Europe until 2028, and if the EMA approves a subsequent indication that brings significant clinical benefit in comparison with existing therapies, until 2029. ​

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2022
Segment Information
Segment Information	15. Segment Information ​ The following table presents information about our reportable segments for the three months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ 2022 ​ 2021 ​ ​ U.S. Ex-U.S. Total U.S. Ex-U.S. Total Product revenue ​ $ 24,509 ​ $ 9,738 ​ $ 34,247 ​ $ 31,701 ​ $ 6,352 ​ $ 38,053 ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ Cost of sales - product ​ 4,835 ​ 3,235 ​ 8,070 ​ 6,157 ​ 2,111 ​ 8,268 ​ Cost of sales - intangible asset amortization ​ 620 ​ 723 ​ 1,343 ​ 620 ​ 723 ​ 1,343 ​ Research and development ​ 40,465 ​ 1,785 ​ 42,250 ​ 50,830 ​ 1,975 ​ 52,805 ​ Selling, general and administrative ​ 23,919 ​ 5,294 ​ 29,213 ​ 24,321 ​ 5,620 ​ 29,941 ​ Other operating expenses ​ ​ 3,730 ​ ​ — ​ ​ 3,730 ​ ​ 3,707 ​ ​ — ​ ​ 3,707 ​ Total expenses ​ 73,569 11,037 84,606 85,635 10,429 96,064 Operating loss ​ $ (49,060) ​ $ (1,299) ​ ​ (50,359) ​ $ (53,934) ​ $ (4,077) ​ ​ (58,011) ​ Other income (expense): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense ​ ​ ​ ​ ​ ​ ​ ​ (9,100) ​ ​ ​ ​ ​ ​ ​ ​ (8,037) ​ Foreign currency loss ​ ​ ​ ​ ​ ​ ​ ​ (978) ​ ​ ​ ​ ​ ​ ​ ​ (546) ​ Other income ​ ​ ​ ​ ​ ​ ​ ​ 148 ​ ​ ​ ​ ​ ​ ​ ​ 183 ​ Other income (expense), net ​ ​ ​ ​ ​ ​ ​ ​ (9,930) ​ ​ ​ ​ ​ ​ ​ ​ (8,400) ​ Loss before income taxes ​ ​ ​ ​ ​ ​ ​ ​ (60,289) ​ ​ ​ ​ ​ ​ ​ ​ (66,411) ​ Income tax (expense) benefit ​ ​ ​ ​ ​ ​ ​ ​ 120 ​ ​ ​ ​ ​ ​ ​ ​ 134 ​ Net loss ​ ​ ​ ​ ​ ​ ​ $ (60,169) ​ ​ ​ ​ ​ ​ ​ $ (66,277) ​ ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation ​ All financial information presented includes the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. ​ The unaudited financial statements of Clovis Oncology, Inc. included herein reflect all adjustments that, in the opinion of management, are necessary to fairly state our financial position, results of operations and cash flows for the periods presented herein. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in audited financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). These financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto which are included in our 2021 Form 10-K for a broader discussion of our business and the opportunities and risks inherent in such business. ​
Use of Estimates	Use of Estimates ​ The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and revenue and related disclosures. On an ongoing basis, we evaluate our estimates, including estimates related to revenue deductions, intangible asset impairment, clinical trial accruals and share-based compensation expense. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards ​ In August 2020, the FASB issued guidance that simplifies an issuer’s accounting for debt and equity instruments. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted. We adopted this guidance on January 1, 2022 and there was no material impact on our consolidated financial statements and related disclosures. ​
Revenue Recognition	Revenue Recognition ​ We are currently approved to sell Rubraca in the United States and Europe markets. We distribute our product principally through a limited number of specialty distributor and specialty pharmacy providers, collectively, our customers. Our customers subsequently sell our products to patients and health care providers. Separately, we have arrangements with certain payors and other third parties that provide for government-mandated and privately-negotiated rebates, chargebacks and discounts. ​ Product Revenue ​ Revenue from product sales are recognized when the performance obligation is satisfied, which is when customers obtain control of our product at a point in time, typically upon delivery. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less. ​ Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (“transaction price”), which includes estimates of variable consideration for which reserves are established and which result from price concessions that include rebates, chargebacks, discounts, co-pay assistance, estimated product returns and other allowances that are offered within contracts between us and our customers, health care providers, payors and other indirect customers relating to the sales of our product. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable or a current liability. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we adjust these estimates, which would affect product revenue and earnings in the period such variances become known. ​ Government Rebates ​ GPO and Payor Rebates. ​ Chargebacks ​ Discounts and Fees ​ Co-pay assistance Returns product returns and we currently do not have an accrual for product returns. We will continue to assess our estimate for product returns based on additional historical experience. ​
Cost of Sales	Cost of Sales – Product ​ Product cost of sales consists primarily of materials, third-party manufacturing costs as well as freight and royalties owed to our licensing partners for Rubraca sales. ​ Cost of Sales – Intangible Asset Amortization ​ Cost of sales for intangible asset amortization consists of the amortization of capitalized milestone payments made to our licensing partners upon FDA approval of Rubraca. Milestone payments are amortized on a straight-line basis over the estimated remaining patent life of Rubraca.
Accounts Receivable	Accounts Receivable ​ We provide an allowance for credit losses based on experience and specifically identified risks. Accounts receivable are charged off against the allowance when we determine that recovery is unlikely and we cease collection efforts.
Inventory	Inventory ​ Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out (“FIFO”) basis. Inventories include active pharmaceutical ingredient (“API”), contract manufacturing costs and overhead allocations. We begin capitalizing incurred inventory related costs upon regulatory approval. Prior to regulatory approval, incurred costs for the manufacture of the drugs that could potentially be available to support the commercial launch of our products are recognized as research and development expense. ​ We regularly analyze our inventory levels for excess quantities and obsolescence (expiration), considering factors such as historical and anticipated future sales compared to quantities on hand and the remaining shelf-life of Rubraca. Rubraca finished goods have a shelf-life of four years from the date of manufacture. We expect to sell the finished goods prior to expiration. The API currently has a shelf-life of five years from the date of manufacture but can be retested at an immaterial cost with no expected reduction in potency, thereby extending its shelf-life as needed. We expect to consume substantially all of the API over a period of approximately seven years based on our long-range sales projections of Rubraca. ​ We write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and/or inventory in excess of expected sales requirements. Expired inventory would be disposed of and the related costs would be written off as cost of product revenue. Inventories that are not expected to be consumed within 12 months following the balance sheet date are classified as long-term inventories. Long-term inventories primarily consist of API. ​ API is currently produced by Lonza. As the API has undergone significant manufacturing specific to its intended purpose at the point it is purchased by us, we classify the API as work-in-process inventory. In addition, we currently manufacture Rubraca finished goods with a single third-party manufacturer. The disruption or termination of the supply of API or the disruption or termination of the manufacturing of our commercial products could have a material adverse effect on our business, financial position and results of operations. API that is written off due to damage and certain costs related to our production train at Lonza are included in Other Operating Expenses on the Consolidated Statements of Operations and Comprehensive Loss. ​ Inventory used in clinical trials is expensed as research and development expense when it has been identified for such use.
Segment Information	Segment Information ​ We have two operating and reportable segments, U.S. and ex-U.S., based on product revenue by geographic areas. We designated our reporting segments based on the internal reporting used by the Chief Operating Decision Maker (“CODM”), which is our Chief Executive Officer, for making decisions and assessing performance as the source of our reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on product revenue by geographic areas. Accordingly, we view our business as two reportable operating segments to evaluate performance, allocate resources, set operational targets and forecast our future period financial results. ​ We manage our assets on a company basis, not by segments, as many of our assets are shared or commingled. Our CODM does not regularly review asset information by reportable segment. The majority of long-lived assets for both segments are located in the United States.
Research and Development Expense	Research and Development Expense ​ Research and development costs are charged to expense as incurred and include, but are not limited to, salary and benefits, share-based compensation, clinical trial activities, drug development and manufacturing, companion diagnostic development and third-party service fees, including contract research organizations and investigative sites. ​ Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred and are reflected on the Consolidated Balance Sheets as prepaid or accrued research and development expenses. ​ Our other significant accounting policies are described in Note 2, Summary of Significant Accounting Policies
Net Loss Per Common Share	Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding using the treasury-stock method for the stock options and RSUs and the if-converted method for the convertible senior notes. As a result of our net losses for the periods presented, all potentially dilutive common share equivalents were considered anti-dilutive and were excluded from the computation of diluted net loss per share.

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Financial Instruments and Fair Value Measurements
Assets Measured at Fair Value on Recurring Basis	The following table identifies our assets and liabilities that were measured at fair value on a recurring basis (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance Level 1 Level 2 Level 3 March 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market investments ​ $ 72,941 ​ $ 72,941 ​ $ — ​ $ — ​ Total assets at fair value ​ $ 72,941 ​ $ 72,941 ​ $ — ​ $ — ​ December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market investments ​ $ 72,934 ​ $ 72,934 ​ $ — ​ $ — ​ Total assets at fair value ​ $ 72,934 ​ $ 72,934 ​ $ — ​ $ — ​

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2022
Inventories
Schedule of Inventories	The following table presents inventories as of March 31, 2022 and December 31, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ 2022 2021 Work-in-process $ 83,462 $ 85,084 Finished goods, net ​ 37,160 ​ 38,452 Total inventories $ 120,622 $ 123,536

Other Current Assets (Tables)

Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2022
Other Current Assets
Schedule Of other current assets	Other current assets were comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2022 2021 Prepaid insurance ​ $ 3,772 ​ $ 794 ​ Prepaid IT ​ ​ 593 ​ ​ 769 ​ Prepaid variable considerations ​ ​ 1,483 ​ ​ 1,336 ​ Prepaid expenses - other ​ 3,474 ​ 1,936 ​ Value-added tax ("VAT") receivable ​ ​ 5,519 ​ ​ 4,307 ​ Receivable - other ​ 1,661 ​ 2,499 ​ Other ​ 64 ​ 65 ​ Total ​ $ 16,566 ​ $ 11,706 ​

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
	Mar. 31, 2022
Intangible Assets and Goodwill
Intangible assets related to capitalized milestones under license agreements	Intangible assets related to capitalized milestones under license agreements consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2022 2021 Intangible asset - milestones ​ $ 79,850 ​ $ 79,850 Accumulated amortization ​ (20,821) ​ (19,479) Total intangible asset, net ​ $ 59,029 ​ $ 60,371
Estimated future amortization expense for intangible assets	Estimated future amortization expense associated with intangibles is expected to be as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ 2022 (remaining nine months) ​ ​ ​ ​ $ 4,028 2023 ​ ​ ​ ​ ​ 5,371 2024 ​ ​ ​ ​ ​ 5,371 2025 ​ ​ ​ ​ ​ 5,371 2026 ​ ​ ​ ​ ​ 5,371 Thereafter ​ ​ ​ ​ ​ 33,517 ​ ​ ​ ​ ​ $ 59,029

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2022
Other Accrued Expenses
Schedule of other accrued expenses	Other accrued expenses were comprised of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2022 2021 Accrued personnel costs ​ $ 10,459 ​ $ 15,714 ​ Accrued interest payable for convertible senior notes ​ 2,609 ​ 3,283 ​ Income tax payable ​ ​ 871 ​ ​ 1,579 ​ Accrued corporate legal fees and professional services ​ ​ 185 ​ ​ 141 ​ Accrued royalties ​ ​ 5,226 ​ ​ 5,463 ​ Accrued variable considerations ​ ​ 17,907 ​ ​ 17,211 ​ Accrued legal settlement loss ​ ​ 2,325 ​ ​ 2,325 ​ Accrued expenses - other ​ 5,048 ​ 5,155 ​ Total ​ $ 44,630 ​ $ 50,871 ​

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases
Schedule of components of lease expense and related cash flows	The components of lease expense and related cash flows were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ Three months ended March 31, ​ 2022 2021 Lease cost ​ ​ ​ ​ ​ ​ Finance lease cost: ​ ​ ​ ​ ​ ​ Amortization of right-of-use assets ​ $ — ​ $ 474 Interest on lease liabilities ​ — ​ 185 Operating lease cost ​ 1,215 ​ 1,253 Short-term lease cost ​ 77 ​ 80 Variable lease cost ​ ​ 639 ​ ​ 523 Total lease cost ​ $ 1,931 ​ $ 2,515 ​ ​ ​ ​ ​ ​ ​ Operating cash flows from finance leases ​ $ — ​ $ 185 Operating cash flows from operating leases ​ $ 1,215 ​ $ 1,253 Financing cash flows from finance leases ​ $ — ​ $ 386 ​
Schedule of weighted-average remaining lease term and weighted-average discount rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 March 31, 2021 ​ Weighted-average remaining lease term (years) ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 5.6 ​ ​ 6.4 ​ Finance leases ​ ​ N/A ​ ​ 4.8 ​ Weighted-average discount rate ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 8% ​ ​ 8% ​ Finance leases ​ ​ N/A ​ ​ 8% ​
Schedule of future minimum commitments due under lease agreements	​ Future minimum commitments due under these lease agreements as of March 31, 2022 are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Leases ​ ​ 2022 (remaining nine months) ​ 4,076 ​ 2023 ​ 4,906 ​ 2024 ​ 4,650 ​ 2025 ​ ​ 4,805 ​ ​ 2026 ​ ​ 4,934 ​ ​ Thereafter ​ 4,899 ​ Present value adjustment ​ ​ (5,710) ​ ​ Present value of lease payments ​ $ 22,560 ​ ​

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt
Summary of Convertible Senior Notes	The following is a summary of our convertible senior notes at March 31, 2022 and December 31, 2021 (principal amount in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Principal Amount ​ Principal Amount ​ ​ ​ ​ ​ Conversion rate per $1,000 ​ ​ March 31, 2022 ​ December 31, 2021 ​ Interest Rate ​ Maturity Date ​ principal amount (shares) 2024 Notes (2019 Issuance) ​ 85,782 ​ 85,782 ​ 4.50% ​ August 1, 2024 ​ 137.2213 2024 Notes (2020 Issuance) ​ ​ 57,500 ​ ​ 57,500 ​ 4.50% ​ August 1, 2024 ​ 160.3334 2025 Notes ​ 300,000 ​ 300,000 ​ 1.25% ​ May 1, 2025 ​ 13.1278 Total ​ ​ 443,282 ​ ​ 443,282 ​ ​ ​ ​ ​ ​ Unamortized debt issuance costs ​ ​ (5,998) ​ ​ (6,510) ​ ​ ​ ​ ​ ​ Convertible senior notes ​ $ 437,284 ​ $ 436,772 ​ ​ ​ ​ ​ ​
Schedule of Maturities of Convertible Notes	Maturities of our convertible notes consisted of the following as of March 31, 2022 (in thousands): ​ ​ ​ ​ ​ 2022 (remaining nine months) ​ $ — 2023 ​ ​ — 2024 ​ ​ 143,282 2025 ​ ​ 300,000 2026 ​ ​ — Thereafter ​ ​ — ​ ​ ​ 443,282 Less debt issuance costs ​ ​ (5,998) Current portion ​ ​ — Long-term portion ​ $ 437,284 ​
Schedule of expected maturities of Finance Agreement	​ ​ ​ ​ ​ 2022 (remaining nine months) ​ $ 8,500 2023 ​ ​ 34,000 2024 ​ ​ 34,000 2025 ​ ​ 79,939 2026 ​ ​ 34,000 Thereafter ​ ​ 122,438 ​ ​ ​ 312,877 Less debt issuance costs ​ ​ (1,232) Less unrecognized interest ​ ​ (117,930) Current portion ​ ​ (17,000) Long-term portion ​ $ 176,715
Schedule of Total Interest Expense Recognized Related to Notes	The following table sets forth total interest expense recognized during the three months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ 2022 2021 Interest on convertible notes ​ $ 2,549 ​ $ 2,977 ​ Amortization of debt issuance costs ​ 558 ​ 639 ​ Interest on finance lease ​ ​ — ​ ​ 185 ​ Interest on borrowings under financing agreement ​ ​ 5,993 ​ ​ 4,210 ​ Other interest ​ ​ — ​ ​ 26 ​ Total interest expense ​ $ 9,100 ​ $ 8,037 ​

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity
Component of Other Comprehensive Income (Loss)	The changes in accumulated balances related to each component of other comprehensive income (loss) are summarized for the three months ended March 31, 2022 and 2021, as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Foreign Currency ​ Unrealized ​ Total Accumulated ​ ​ Translation Adjustments ​ Losses ​ Other Comprehensive Loss ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ Balance at Jan 1, ​ $ (43,291) ​ $ (44,165) ​ $ (139) ​ $ (139) ​ $ (43,430) ​ $ (44,304) ​ Other comprehensive income ​ ​ 435 ​ ​ (80) ​ ​ — ​ ​ — ​ ​ 435 ​ ​ (80) ​ Total before tax ​ ​ (42,856) ​ ​ (44,245) ​ ​ (139) ​ ​ (139) ​ ​ (42,995) ​ ​ (44,384) ​ Tax effect ​ — ​ ​ — ​ — ​ ​ — ​ — ​ ​ — ​ Balance at March 31, ​ $ (42,856) ​ $ (44,245) ​ $ (139) ​ $ (139) ​ $ (42,995) ​ $ (44,384) ​

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-Based Compensation
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations	Share-based compensation expense for all equity-based programs, including stock options, restricted stock units and the employee stock purchase plan, for the three months ended March 31, 2022 and 2021 was recognized in the accompanying Consolidated Statements of Operations and Comprehensive Loss as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ 2022 2021 Research and development ​ $ 3,229 ​ $ 2,876 ​ ​ Selling, general and administrative ​ 3,403 ​ 1,163 ​ ​ Total share-based compensation expense ​ $ 6,632 ​ $ 4,039 ​ ​
Summary of Stock Options Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ Weighted ​ Average ​ Aggregate ​ ​ ​ ​ Average ​ Remaining ​ Intrinsic ​ ​ Number of ​ Exercise ​ Contractual ​ Value ​ ​ Options ​ Price ​ Term (Years) ​ (Thousands) Outstanding at December 31, 2021 ​ 7,010,039 ​ $ 33.36 ​ ​ Granted ​ 516,250 ​ ​ 1.96 ​ ​ Exercised ​ — ​ ​ — ​ ​ Forfeited ​ (342,217) ​ ​ 26.30 ​ ​ Outstanding at March 31, 2022 ​ 7,184,072 ​ $ 31.44 5.7 ​ $ 35 ​ Vested and expected to vest at March 31, 2022 ​ 6,963,967 ​ $ 32.29 5.6 ​ $ 28 ​ Vested and exercisable at March 31, 2022 ​ 5,384,051 ​ $ 39.88 4.6 ​ $ — ​
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award	The following table summarizes information about our stock options as of and for the three months ended March 31, 2022 and 2021 (in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ 2022 2021 Weighted-average grant date fair value per share ​ $ 1.47 ​ $ 4.94 ​ Intrinsic value of options exercised ​ $ — ​ $ 14 ​ Cash received from stock option exercises ​ $ — ​ $ 27 ​
Summary of activity related to our unvested RSUs	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average ​ ​ Number of ​ Grant Date ​ ​ Units ​ Fair Value Unvested at December 31, 2021 ​ 3,683,422 ​ $ 8.36 ​ Granted ​ 2,749,649 ​ 1.95 ​ Vested ​ (889,273) ​ 8.43 ​ Forfeited ​ (70,411) ​ 6.96 ​ Unvested at March 31, 2022 ​ 5,473,387 ​ $ 5.15 ​ Expected to vest after March 31, 2022 ​ 4,537,263 ​ $ 5.47 ​

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2022
Net Loss Per Common Share
Shares Outstanding Excluded from Calculation of Diluted Net Loss Per Share	The shares outstanding at the end of the respective periods presented in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ ​ 2022 2021 Common shares under stock incentive plans ​ 5,971 ​ 5,719 ​ Convertible senior notes ​ 24,928 ​ 25,969 ​ Total potential dilutive shares ​ 30,899 ​ 31,688 ​

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2022
Segment Information
Schedule of information about reportable segments	The following table presents information about our reportable segments for the three months ended March 31, 2022 and 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ended March 31, ​ 2022 ​ 2021 ​ ​ U.S. Ex-U.S. Total U.S. Ex-U.S. Total Product revenue ​ $ 24,509 ​ $ 9,738 ​ $ 34,247 ​ $ 31,701 ​ $ 6,352 ​ $ 38,053 ​ Operating expenses: ​ ​ ​ ​ ​ ​ ​ Cost of sales - product ​ 4,835 ​ 3,235 ​ 8,070 ​ 6,157 ​ 2,111 ​ 8,268 ​ Cost of sales - intangible asset amortization ​ 620 ​ 723 ​ 1,343 ​ 620 ​ 723 ​ 1,343 ​ Research and development ​ 40,465 ​ 1,785 ​ 42,250 ​ 50,830 ​ 1,975 ​ 52,805 ​ Selling, general and administrative ​ 23,919 ​ 5,294 ​ 29,213 ​ 24,321 ​ 5,620 ​ 29,941 ​ Other operating expenses ​ ​ 3,730 ​ ​ — ​ ​ 3,730 ​ ​ 3,707 ​ ​ — ​ ​ 3,707 ​ Total expenses ​ 73,569 11,037 84,606 85,635 10,429 96,064 Operating loss ​ $ (49,060) ​ $ (1,299) ​ ​ (50,359) ​ $ (53,934) ​ $ (4,077) ​ ​ (58,011) ​ Other income (expense): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense ​ ​ ​ ​ ​ ​ ​ ​ (9,100) ​ ​ ​ ​ ​ ​ ​ ​ (8,037) ​ Foreign currency loss ​ ​ ​ ​ ​ ​ ​ ​ (978) ​ ​ ​ ​ ​ ​ ​ ​ (546) ​ Other income ​ ​ ​ ​ ​ ​ ​ ​ 148 ​ ​ ​ ​ ​ ​ ​ ​ 183 ​ Other income (expense), net ​ ​ ​ ​ ​ ​ ​ ​ (9,930) ​ ​ ​ ​ ​ ​ ​ ​ (8,400) ​ Loss before income taxes ​ ​ ​ ​ ​ ​ ​ ​ (60,289) ​ ​ ​ ​ ​ ​ ​ ​ (66,411) ​ Income tax (expense) benefit ​ ​ ​ ​ ​ ​ ​ ​ 120 ​ ​ ​ ​ ​ ​ ​ ​ 134 ​ Net loss ​ ​ ​ ​ ​ ​ ​ $ (60,169) ​ ​ ​ ​ ​ ​ ​ $ (66,277) ​

Nature of Business (Details)

Nature of Business (Details) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Dec. 31, 2020item	Mar. 31, 2022USD ($)itemsegmentproduct	May 02, 2022$ / shares
Number of operating segments | segment		2
Number of other product candidates | product		2
Number of INDs	2
Number of targets for collaborative discovery		3
Number of pathways inhibited		3
Number of cohorts		3
Capacity to issue additional shares of common stock | $		$ 16.5
Sale of stock, price per share | $ / shares			$ 2.03
Minimum estimated number of months operating plan funded		12 months
Minimum
Number of chemotherapies received by an adult patient		2
Number of prior lines of platinum based chemotherapy received by patient		2

Summary of Significant Policies

Summary of Significant Policies (Details)	3 Months Ended
	Mar. 31, 2022segment
Schedule Of Significant Accounting Policies
Amortization period of the asset	true
Shelf-life of API	5 years
Consumption period of API	7 years
Number of operating segments	2
Number of reportable segments	2
Rucaparib
Schedule Of Significant Accounting Policies
Shelf life of inventory	4 years
Minimum
Schedule Of Significant Accounting Policies
Payment terms number of days	30 days
Maximum
Schedule Of Significant Accounting Policies
Payment terms number of days	60 days

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements (Details) - Recurring - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value Measurements
Assets at fair value	$ 72,941	$ 72,934
Liabilities at fair value	0
Money market investments
Fair Value Measurements
Assets at fair value	72,941	72,934
Fair Value, Inputs, Level 1
Fair Value Measurements
Assets at fair value	72,941	72,934
Fair Value, Inputs, Level 1 | Money market investments
Fair Value Measurements
Assets at fair value	72,941	72,934
Fair Value, Inputs, Level 2 | Money market investments
Fair Value Measurements
Assets at fair value	0	0
Fair Value, Inputs, Level 3
Fair Value Measurements
Assets at fair value	0	0
Fair Value, Inputs, Level 3 | Money market investments
Fair Value Measurements
Assets at fair value	$ 0	$ 0

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value Measurements
Principal amount outstanding	$ 437,284	$ 436,772
2024 Notes (2019 Issuance)
Fair Value Measurements
Principal amount outstanding	84,500
Convertible senior notes, fair value	57,500
2024 Notes (2020 Issuance)
Fair Value Measurements
Principal amount outstanding	56,900
Convertible senior notes, fair value	44,000
Convertible Senior Unsecured Notes 2025 Notes
Fair Value Measurements
Principal amount outstanding	295,900
Convertible senior notes, fair value	$ 205,100

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventories
Work-in-process	$ 83,462	$ 85,084
Finished goods, net	37,160	38,452
Total inventories	$ 120,622	$ 123,536

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Other Current Assets
Prepaid insurance	$ 3,772	$ 794
Prepaid IT	593	769
Prepaid variable considerations	1,483	1,336
Prepaid expenses - other	3,474	1,936
Value-added tax ("VAT") receivable	5,519	4,307
Receivable - other	1,661	2,499
Other	64	65
Total	$ 16,566	$ 11,706

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - Licensing Agreements - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Finite Lived Intangible Assets [Line Items]
Intangible asset - milestones	$ 79,850	$ 79,850
Accumulated amortization	(20,821)	(19,479)
Total intangible asset, net	$ 59,029	$ 60,371

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Licensing Agreements
Finite Lived Intangible Assets
Amortization of Intangible Assets	$ 1.3	$ 1.3

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Estimated Future Amortization (Details) - Licensing Agreements - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Finite Lived Intangible Assets
2022 (remaining nine months)	$ 4,028
2023	5,371
2024	5,371
2025	5,371
2026	5,371
Thereafter	33,517
Total intangible asset, net	$ 59,029	$ 60,371

Other Accrued Expenses (Details

Other Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Other Accrued Expenses
Accrued personnel costs	$ 10,459	$ 15,714
Accrued interest payable for convertible senior notes	2,609	3,283
Income tax payable	871	1,579
Accrued corporate legal fees and professional services	185	141
Accrued royalties	5,226	5,463
Accrued variable considerations	17,907	17,211
Accrued legal settlement loss	2,325	2,325
Accrued expenses - other	5,048	5,155
Total	$ 44,630	$ 50,871

Leases - Components of lease ex

Leases - Components of lease expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Lessee Disclosure [Abstract]
Amortization of right-of-use assets		$ 474
Interest on lease liabilities		185
Operating lease cost	$ 1,215	1,253
Short-term lease cost	77	80
Variable lease cost	639	523
Total lease cost	1,931	2,515
Cash flows from leases
Operating cash flows from finance leases		185
Operating cash flows from operating leases	$ 1,215	1,253
Financing cash flows from finance leases		$ 386

Leases - Weighted Average (Deta

Leases - Weighted Average (Details)	Mar. 31, 2022	Mar. 31, 2021
Weighted-average remaining lease term (years)
Operating leases	5 years 7 months 6 days	6 years 4 months 24 days
Finance leases		4 years 9 months 18 days
Weighted-average discount rate
Operating leases	8.00%	8.00%
Finance leases		8.00%

Leases - Future minimum commitm

Leases - Future minimum commitments (Details) $ in Thousands	Mar. 31, 2022USD ($)
Operating Leases
2022 (remaining nine months)	$ 4,076
2023	4,906
2024	4,650
2025	4,805
2026	4,934
Thereafter	4,899
Present value adjustment	(5,710)
Present value of lease payments	$ 22,560
Operating Lease, Liability, Statement of Financial Position [Extensible List]	us-gaap:OtherLiabilitiesCurrent, us-gaap:OtherLiabilitiesNoncurrent

Debt (Details)

Debt (Details) $ in Thousands	May 01, 2019USD ($)countrysiteitem	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)
Debt Instrument
Aggregate principal amount		$ 443,282	$ 443,282
Unamortized debt issuance costs		(5,998)	(6,510)
Principal amount outstanding		$ 437,284	436,772
Debt instrument repurchase percentage		100.00%
Borrowings under financing agreement - less current portion		$ 176,715	169,956
Sixth Street Partners, LLC
Debt Instrument
Number of patients | item	1,000
Interest rate based on amount borrowed	9.75%
Maximum amount required to be repaid		350,000
Percentage of royalty payment received	19.50%
Percentage of other amounts received	19.50%
Quarterly payments based on a certain percentage of revenues		8,500
Quarterly payments with label portion expanded by FDA		$ 13,500
Ratio of repayment amount		2
Effective interest rate		13.70%
Sixth Street Partners, LLC | Date is prior to Repayment Start Date
Debt Instrument
Debt Instrument Ratio		1.75%
Sixth Street Partners, LLC | Date is after Repayment Start Date
Debt Instrument
Debt Instrument Ratio		2.00%
Sixth Street Partners, LLC | Minimum
Debt Instrument
Number of sites | site	270
Number of countries | country	25
Sixth Street Partners, LLC | Maximum
Debt Instrument
Aggregate principal amount	$ 175,000
2024 Notes (2019 Issuance)
Debt Instrument
Aggregate principal amount		$ 85,782	85,782
Convertible senior notes, interest rate		4.50%
Convertible senior notes, maturity date		Aug. 1, 2024
Conversion rate per $1,000 principal amount (shares)		137.2213
Principal amount outstanding		$ 84,500
2024 Notes (2020 Issuance)
Debt Instrument
Aggregate principal amount		$ 57,500	57,500
Convertible senior notes, interest rate		4.50%
Convertible senior notes, maturity date		Aug. 1, 2024
Conversion rate per $1,000 principal amount (shares)		160.3334
Principal amount outstanding		$ 56,900
2025 Notes
Debt Instrument
Aggregate principal amount		$ 300,000	$ 300,000
Convertible senior notes, interest rate		1.25%
Convertible senior notes, maturity date		May 1, 2025
Conversion rate per $1,000 principal amount (shares)		13.1278
Borrowing Exceeds $166.5 million | Sixth Street Partners, LLC
Debt Instrument
Aggregate principal amount		$ 175,000
Interest rate based on amount borrowed		10.25%
Maximum amount required to be repaid		$ 166,500
Borrowing Exceeds $166.5 million | Sixth Street Partners, LLC | Maximum
Debt Instrument
Quarterly payments based on a certain percentage of revenues		8,900
Quarterly payments with label portion expanded by FDA		14,200
Scenario | Sixth Street Partners, LLC | Minimum
Debt Instrument
Borrowings under financing agreement - less current portion		$ 166,500

Debt - Maturities for Convertib

Debt - Maturities for Convertible Senior Notes (Details) $ in Thousands	Mar. 31, 2022USD ($)
Debt
2024	$ 143,282
2025	300,000
Total	443,282
Less debt issuance costs	(5,998)
Long-term portion	$ 437,284

Debt - Expected maturities of F

Debt - Expected maturities of Financing Agreement (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
2022 (remaining nine months)	$ 8,500
2023	34,000
2024	34,000
2025	79,939
2026	34,000
Thereafter	122,438
Expected maturities of financing agreement including debt issuance costs	312,877
Less debt issuance costs	(1,232)
Less unrecognized interest	(117,930)
Current portion	(17,000)
Long-term portion	$ 176,715	$ 169,956

Debt - Interest expense recogni

Debt - Interest expense recognized (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt
Interest on convertible notes	$ 2,549	$ 2,977
Amortization of debt issuance costs	558	639
Interest on finance lease		185
Interest on borrowings under financing agreement	5,993	4,210
Other interest		26
Total interest expense	$ 9,100	$ 8,037

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) $ in Thousands	Nov. 16, 2021USD ($)shares	Aug. 16, 2021USD ($)	May 17, 2021USD ($)	Sep. 15, 2021USD ($)shares	Jun. 09, 2021USD ($)shares	Mar. 03, 2022USD ($)shares	Mar. 31, 2022USD ($)Vote
Class Of Stock [Line Items]
Number of votes per common share | Vote							1
Proceeds from offering							$ 28,636
At the market offering
Class Of Stock [Line Items]
Aggregate offering price		$ 125,000	$ 75,000
Common shares issued in a public offering | shares	731,292			9,379,976	13,492,231	13,870,410
Gross proceeds from offering	$ 3,100			$ 43,000	$ 75,000	$ 29,800
Proceeds from offering	$ 3,000			$ 41,500	$ 72,500	$ 28,600

Stockholders' Equity - Accumula

Stockholders' Equity - Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Accumulated Other Comprehensive Loss
Beginning balance	$ (43,430)	$ (44,304)
Other comprehensive income	435	(80)
Total before tax	(42,995)	(44,384)
Tax effect	0	0
Ending balance	(42,995)	(44,384)
Reclassifications out of accumulated other comprehensive loss	0	0
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Loss
Beginning balance	(43,291)	(44,165)
Other comprehensive income	435	(80)
Total before tax	(42,856)	(44,245)
Tax effect	0	0
Ending balance	(42,856)	(44,245)
Unrealized Losses
Accumulated Other Comprehensive Loss
Beginning balance	(139)	(139)
Total before tax	(139)	(139)
Tax effect	0	0
Ending balance	$ (139)	$ (139)

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award
Share-based compensation expense, tax benefit recognized	$ 0	$ 0
Closing stock price	$ 2.02
Common shares under stock incentive plans
Share Based Compensation Arrangement By Share Based Payment Award
Unrecognized stock-based compensation expense related to unvested stock options	$ 6.2
Unrecognized stock-based compensation expense related to non-vested options and/or RSUs, weighted-average remaining vesting period	1 year 8 months 12 days
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award
Unrecognized stock-based compensation expense related to non-vested options and/or RSUs, weighted-average remaining vesting period	2 years
Unrecognized stock-based compensation expense related to unvested RSUs	$ 25.6

Share-Based Compensation - Shar

Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations
Total Share-based compensation expense	$ 6,632	$ 4,039
Research and development
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations
Total Share-based compensation expense	3,229	2,876
General and administrative
Share-Based Compensation Expense Recognized in Accompanying Statements of Operations
Total Share-based compensation expense	$ 3,403	$ 1,163

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Options Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Share-Based Compensation
Beginning Balance, Number of Options Outstanding | shares	7,010,039
Granted, Number of Options | shares	516,250
Forfeited, Number of Options | shares	(342,217)
Ending Balance, Number of Options Outstanding | shares	7,184,072
Vested and expected to vest, Number of Options Outstanding | shares	6,963,967
Vested and exercisable, Number of Options Outstanding | shares	5,384,051
Beginning Balance, Weighted Average Exercise Price | $ / shares	$ 33.36
Granted, Weighted Average Exercise Price | $ / shares	1.96
Forfeited, Weighted Average Exercise Price | $ / shares	26.30
Ending Balance, Weighted Average Exercise Price | $ / shares	31.44
Vested and expected to vest, Weighted Average Exercise Price | $ / shares	32.29
Vested and exercisable, Weighted Average Exercise Price | $ / shares	$ 39.88
Outstanding, Weighted Average Remaining Contractual Term (Years)	5 years 8 months 12 days
Vested and expected to vest, Weighted Average Remaining Contractual Term (Years)	5 years 7 months 6 days
Vested and exercisable, Weighted Average Remaining Contractual Term (Years)	4 years 7 months 6 days
Outstanding, Aggregate Intrinsic Value | $	$ 35
Vested and expected to vest, Aggregate Intrinsic Value | $	$ 28

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Compensation
Weighted-average grant date fair value per share	$ 1.47	$ 4.94
Intrinsic value of options exercised		$ 14
Cash received from stock option exercises		$ 27

Share-Based Compensation - RSUs

Share-Based Compensation - RSUs Activity (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award
Number of Units, Unvested as of Beginning Balance | shares	3,683,422
Number of Units, Granted | shares	2,749,649
Number of Units, Vested | shares	(889,273)
Number of Units, Forfeited | shares	(70,411)
Number of Units, Unvested as of Ending Balance | shares	5,473,387
Expected to vest after March 31, 2022 | shares	4,537,263
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 8.36
Weighted Average Grant Date Fair Value, Granted | $ / shares	1.95
Weighted Average Grant Date Fair Value, Vested | $ / shares	8.43
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	6.96
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	5.15
Weighted Average Grant Date Fair Value, Expected to vest after March 31, 2022 | $ / shares	$ 5.47

License Agreements (Details)

License Agreements (Details) $ in Millions	Nov. 19, 2013USD ($)	Sep. 30, 2021USD ($)	Apr. 30, 2021USD ($)	Dec. 31, 2020item	Feb. 29, 2020item	Sep. 30, 2019USD ($)	Jun. 30, 2011USD ($)	Oct. 31, 2008	Mar. 31, 2022USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2020USD ($)
License Agreements
Number of INDs | item				2
3B Pharmaceuticals
License Agreements
Percentage of non-royalty consideration payable on sublicense agreements									34.00%
License Agreements Licensor Pfizer | Rucaparib | Minimum
License Agreements
Annual sales target for sales milestone payments									$ 250
License Agreements Licensor Pfizer | Rucaparib | Maximum
License Agreements
Maximum potential future development, regulatory milestone payments									8
Additional maximum payments payable on attaining the sales target									$ 170
License Agreement Terms | 3B Pharmaceuticals
License Agreements
Milestone payments		$ 3.3	$ 2.2
Acquired in-process research and development						$ 9.4
Number of INDs | item				2
Number of additional undisclosed targets | item					3
Research and development expense										$ 2.1
Percentage of royalty on net sales									6.00%
License Agreement Terms | License Agreements Licensor Pfizer | Rucaparib
License Agreements
Upfront payment							$ 7
Milestones paid to Pfizer prior to FDA approval							$ 1.4
Milestone payments											$ 82.5
License Agreement Terms | Advenchen Laboratories LLC | License Agreements Lucitanib
License Agreements
Percentage of non-royalty consideration payable on sublicense agreements								25.00%
Milestone payment obligation	$ 65

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share
Total potential dilutive shares	30,899	31,688
Common shares under stock incentive plans
Antidilutive Securities Excluded From Computation Of Earnings Per Share
Total potential dilutive shares	5,971	5,719
Convertible senior notes
Antidilutive Securities Excluded From Computation Of Earnings Per Share
Total potential dilutive shares	24,928	25,969

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Thousands	Mar. 04, 2022item	Jun. 16, 2021USD ($)	Nov. 10, 2019plaintiff	Jun. 20, 2017patent	Mar. 31, 2017shareholder	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)
Commitments and Contingencies
Purchase commitments						$ 39,600
Payments on derecognition of lease components		$ 1,100
Number of putative shareholders | shareholder					2
Number of new independent directors agreed to elect | item	1
Litigation expense						$ 2,325	$ 2,325
Number of patents in salt and polymorph patent family | patent				2
Number of opponents | plaintiff			1
Number of years regulatory exclusivity in Europe						10 years
Number of years possible additional regulatory exclusivity						1 year

Segment Information - Reportabl

Segment Information - Reportable segments (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Product revenue	$ 34,247	$ 38,053
Product revenue - extensible list	Product	Product
Operating expenses:
Research and development	$ 42,250	$ 52,805
Selling, general and administrative	29,213	29,941
Other operating expenses	3,730	3,707
Total expenses	84,606	96,064
Operating loss	(50,359)	(58,011)
Other income (expense):
Interest expense	(9,100)	(8,037)
Foreign currency loss	(978)	(546)
Other income	148	183
Other income (expense), net	(9,930)	(8,400)
Loss before income taxes	(60,289)	(66,411)
Income tax benefit	120	134
Net loss	(60,169)	(66,277)
Product
Operating expenses:
Cost of sales	8,070	8,268
Intangible asset amortization
Operating expenses:
Cost of sales	1,343	1,343
U.S.
Segment Reporting Information [Line Items]
Product revenue	$ 24,509	$ 31,701
Product revenue - extensible list	Product	Product
Operating expenses:
Research and development	$ 40,465	$ 50,830
Selling, general and administrative	23,919	24,321
Other operating expenses	3,730	3,707
Total expenses	73,569	85,635
Operating loss	(49,060)	(53,934)
U.S. | Product
Operating expenses:
Cost of sales	4,835	6,157
U.S. | Intangible asset amortization
Operating expenses:
Cost of sales	620	620
ex U.S.
Segment Reporting Information [Line Items]
Product revenue	$ 9,738	$ 6,352
Product revenue - extensible list	Product	Product
Operating expenses:
Research and development	$ 1,785	$ 1,975
Selling, general and administrative	5,294	5,620
Total expenses	11,037	10,429
Operating loss	(1,299)	(4,077)
ex U.S. | Product
Operating expenses:
Cost of sales	3,235	2,111
ex U.S. | Intangible asset amortization
Operating expenses:
Cost of sales	$ 723	$ 723